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Abstract 
Improved oral delivery of vitamins and antioxidants via food, beverages or supplements 
can be achieved by encapsulation of the bioactive component in biodegradable and 
biocompatible colloidal and nanoparticle systems. Mucoadhesive chitosan/Poly (D, L-lactide-co-
glycolide) particles were investigated as a means to control the release of bioactive compounds 
such as vitamin E in the gastrointestinal (GI) tract. Chitosan/PLGA particles with entrapped 
alpha-tocopherol at different initial loadings were synthesized by emulsion evaporation method, 
compared against PLGA particles in terms of their physical properties, stability, and 
gastrointestinal release profiles. Chi/PLGA particles of 250 ± 8.9 nm with a zeta potential of  61 
± 3.1 mV, and 0.232 polydispersity were formed at 16% theoretical initial loading (with respect 
to PLGA) and 0.6 w/v% chitosan. Chitosan/PLGA particles were stable below pH 5 and above 
pH 8; at low pHs particles were positively charged whereas at high pHs they had a negative zeta 
potential. Particles precipitated between pH 5 and 8. Stability of the particles as function of time 
revealed that PLGA particles remained stable with an average particle size, zeta-potential and 
PDI of 120 nm, − 65 mV, 0.3, respectively, over a day under all gastrointestinal conditions, 
except pH 1.5, where the particle system approached point of zero charge and aggregated. 
Similarly, Chitosan/PLGA particles aggregated around neutral pHs, but were well dispersed at 
pH 1.5. The particle release kinetics in simulated gastric and intestinal environments for different 
initial alpha-tocopherol loadings was studied. Faster alpha-tocopherol release occurred for 8% 
initial loading under gastric conditions compared to 16% and 24% alpha-tocopherol initial 
loadings. Initial loading had no significant effect on the intestinal release of αT. The PLGA 
particle systems also exhibited a faster release rate compared to Chitosan/PLGA particles mostly 
due to smaller size. 40% alpha-tocopherol was released within 2 hours under gastric conditions, 
and 54 % released after 5 days under intestinal conditions, from PLGA particles. In comparison, 
xi 
 
Chi/PLGA particles released only 20 % under gastric and 58 % under intestinal conditions. 
Hence, Chi/PLGA were found superior in increasing the residence time of alpha-tocopherol in 
the GI tract which theoretically could be associated with improved αT bioavailability. 
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Chapter 1 Introduction 
1.1 Vitamins and Health Benefits 
Vitamins are a class of nutrients essential for reproduction, repair, growth and development 
of the human system (Packer, Slater et al. 1979; Mann, Nesheim et al. 1990; Combs 1998; Singh, 
Ye et al. 2009) that are not synthesized by the human body. Hence, vitamins required for daily 
functions are obtained from food, beverages, or from supplements in a tablet form. There are two 
types of vitamins based on their solubility; fat-soluble vitamins, such as vitamins A, D, E, K, and 
water soluble vitamins, such as B and C vitamins.   
Multiple vitamin formulations and routes of delivery have been explored in an attempt to 
increase the solubility of fat soluble vitamins. Transdermal and dermal delivery of vitamins A 
and E (Taepaiboon, Rungsardthong et al. 2007), oral delivery of vitamin B2 (Bajpai, Bajpai et al. 
2002), ocular delivery of vitamin B12 (Kahn 2005), and intravenous administration of vitamins 
(Greene, Smith et al. 1991) were attempted to increase the efficiency of vitamin uptake. Though 
multiple routes of delivery are available, the oral route is the most preferred by patients due to its 
ease and less invasive means of drug administration (Ponchel and Irache 1998; Stevens and 
Ghazi 2000; Delie and Blanco-Príeto 2005; Sahana, Mittal et al. 2008; Lai and Lin 2009). In 
response, biopharmaceutical companies offer an increase in oral formulations of drugs to target 
the vast market that prefers this form of administration (Kalorama 2007).  
Although oral delivery is the most preferred route, it does pose some problems in 
absorption of certain drugs, including lipophilic bioactives and vitamins. Some of the problems 
encountered in oral administration of lipophilic vitamins such as vitamin E include low mucosal 
permeability, low solubility of the compound in the mucosal fluids, and premature elimination 
prior to complete absorption of the lipophilic vitamins in the gastrointestinal environment 
(Ponchel and Irache 1998; Sahana, Mittal et al. 2008).  
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Figure 1.1 Vitamin E family formed of   
α, β, γ, δ tocopherols and tocotrienols 
Of the lipophilic vitamins, vitamin E is the most potent antioxidant known to prevent 
cellular damage surged from chemical reactions that involve reactive oxygen species (Halliwell 
and Gutteridge 1995; Halliwell 1999; Knight 2000; Young and Woodside 2001). For that reason, 
vitamin E, specifically alpha-tocopherol, was selected as a model lipophilic vitamin in this study. 
1.1.1 Vitamin E − Structure, Function and Transport 
Forms of tocopherols and tocotrienols with 
similar biological activity are collectively known as 
vitamin E (Achim Stocker 2000) (Figure 1.1). The 
most biologically active form of vitamin E is α- 
tocopherol (αT) (Burton and Ingold 1986). Alpha-
tocophetol daily recommended intake is 
approximately 5−20 mg, with no reported toxicity 
below 400 mg per day (USFDA/CFSAN 1975).  
When vitamin E is introduced in the diet, it 
travels down the GI tract, and it gets absorbed in the 
small intestine with other lipids and fatty acids 
(Figure 1.2). Vitamin E vitamers are highly acid resistant (Gerald F. Combs 1998), and thus it is 
suspected that no significant breakdown of vitamin E occurs in the mouth or stomach (Ronald 
Eitenmiller 2004) prior to intestinal translocation, where majority of the absorption occurs via 
absorptive enterocytes. The vitamin absorption is facilitated by two pathways, the HDL or 
chylomicron secretion pathway. The most commonly seen pathway is the chylomicron secretion 
in the presence of dietary lipids and microsomal triglyceride transfer protein. At the intestinal 
level, lipophilic vitamins, such as vitamin E, are packaged into water-soluble vesicles composed 
of phospholipids and bile salts which transport the fat-soluble vitamins, lipids and fatty-acids to 
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the enterocytes (Bjorneboe, Bjorneboe et al. 1990; Borel, Pasquier et al. 2001). The vitamins 
along with the lipids and fatty acids are absorbed into the enterocytes, where they are synthesized 
into complex lipids and are assembled into chylomicrons (Ronald Eitenmiller 2004) with the aid 
of the Golgi apparatus. The chylomicrons, varying in size from 75 – 450 nm (Nayak, Harrison et 
al. 2001), are secreted into the lymphatic system (Cooper 1997) from the enterocytes by 
exocytosis. The chylomicrons undergo hydrolysis of the triglyceride groups by the lipoprotein 
lipase, leading to the formation of chylomicron remnants. The liver takes up the chylomicron 
remnants from the lymphatic circulation through the hepatic portal vein. Once in the liver, the 
chylomicron remnants may undergo a cascade of pathways depending on size (Cooper 1997), 
during which vitamin E is released (Ronald Eitenmiller 2004), sorted, re-packaged, and secreted 
into the plasma from the liver in high density lipoprotein, low-density lipoproteins, or very low-
density lipoproteins (Kayden and Traber 1993). The efficiency of absorption of vitamin E and αT 
acetate, respectively, were reported to be approximately 36% and 44% in normal subjects 
(Klatskin and Molander 1952), when administered in the free form. 
Multiple studies (discussed in the following section) have sought to encapsulate vitamin 
E in lipid and polymeric matrices to ease some of the problems encountered; on-shelf stability, 
aqueous solubility, and absorptive uptake (Figure 1.2), during transport and absorption. 
1.1.2 Vitamin E Delivery Systems 
Chen and Wagner (2004) improved vitamin E stability on-shelf up to 6 months in 
beverages by microencapsulating the vitamin with starch using ultra-high pressure 
homogenization (Chen and Wagner 2004). Duclairoir (2002) also addressed the vitamin E on-
shelf stability, to protect the antioxidative property of the vitamin from light, oxygen and 
temperature by entrapping the vitamin in 900 nm wheat gliadin particles  (Duclairoir 2002).   
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Figure 1.2 Vitamin E transport and absorption, via chylomicron pathway, highlighting the problems associated with αT uptake 
and bioavailability (bold arrows) 
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Zigoneanu et al (2006) reported synthesis of 16 % theoretical loading PLGA (αT) nanoparticles 
as small as 53 nm, using sodium dodecyl sulfate (SDS) as a surfactant, and of 206 nm when 
polyvinyl alcohol (PVA) was employed as an emulsifier. A high entrapment efficiency of 89 % 
and 95 % was reported for the 8 % and 16 % αT theoretical loading, respectively. The in vitro 
release studies showed that in 48 hrs a 100 % and 90 % αT release was achieved for the 8 % and 
16 % theoretical loading, respectively (Zigoneanu 2006). The in vitro studies by Zigoneanu 
(2006) did not mimic physiological conditions.  
In vivo studies were carried out with various systems in an attempt to show improved 
vitamin uptake. A study performed on horses showed that αT in the micellized form had higher 
plasma concentration compared to other stereoisomers of the vitamin (Fiorellino, Lamprecht et 
al. 2009). Absorption comparison of vitamin E in capsules compared to NanoSolve (Lipoid 
GmbH, Ludwigshafen, Germany), a delivery vehicle made of purified phospholipids, showed 
that blood vitamin E was depleted at a faster rate than absorped, in its natural form; but showed 
increased absorption when enstraped in NanoSolve (Wajda, Zirkel et al. 2007). Although a 10 
fold increase in absorption with respect to the baseline was proven with the use of nanosized 
capsules with purified phospholipids, the maximum concentration attained was roughly 
2.35μmol/L after 6 hours of administration, which is less than 50 % of the initial dose. The low 
uptake could be attributed to a saturation mechanism associated with αT transport protein or 
premature elimination of αT from the alimentary canal prior to complete absorption.  
A chitosan coated PLGA particle stabilized by lecithin was chosen as the appropriate 
vehicle to protect and increase the residence time of the vitamin in the GI tract. The proposed 
system would (1) increase the bioaccessibility of a model lipophilic vitamin (αT) by entrapping it 
in designed matrices that would attach to the mucosal tissue, and release the vitamin over time, 
(2) ensure that the lipophilic vitamin is soluble in aqueous media to facilitate administration and 
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transport within the gastrointestinal fluids, and (3) counteract the transport protein rate limitation 
by releasing the vitamin over a long period of time, which would avoid an instant overload in the 
liver and would achieve a higher vitamin bioavailability.  
Safety of the Chitosan/PLGA particulate system was a major concern considering that the 
bio-nano interaction of polymeric nanoparticles has not yet been extensively analyzed for 
cytotoxicity in humans  (Taskforce 2007). It is known that particle size, surface charge and 
hydrophobicity play a vital role in the ability of particles to be translocated through the cell 
(Jung, Kamm et al. 2000). Desai et al, 1996, reported a 15-250 fold increase in uptake of 100 nm 
bovine serum albumin loaded PLGA nanoparticles compared to larger particles (Desai, 
Labhasetwar et al. 1996). Jung et al, 2000, reviewed studies on particle transport ranging from 
100 nm to 26 µm in size, and concluded that particles < 300 nm have greater uptake by the 
enterocytes (Jung, Kamm et al. 2000). Literature also shows that mucoadhesive particle systems 
are desired because they have a decreased translocation into the cells and are eliminated in the 
process of mucus turnover (Ponchel and Irache 1998; Jung, Kamm et al. 2000). Chitosan, due to 
its mucoadhesive properties will keep the particle attached to the mucus tissue, and prevent its 
transport into the body, whereas non-mucoadhesive PLGA (αT) particles would be transported 
through the enterocytes (Figure 1.3). This will ensure reduced toxicity from particle degradation 
by-products of the delivery system. With the proposed Chi/PLGA system, the vitamin will be 
constantly supplied for as long as the particles are attached to the mucus covering the 
enterocytes, roughly 3-5 days (Figure 1.3). For added safety, the materials proposed in the 
synthesis are approved as generally recognized as safe (GRAS) by the Food and Drug 
Administration (FDA) for food or pharmaceutical uses.  
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1.2 Objectives 
It is widely recognized that bioavailability of vitamins is affected by the materials and 
properties of the structure in which it is entrapped and delivered. The thrust of this research was 
to understand the mechanisms involved in GI delivery of αT with a particular delivery system 
Chi/PLGA. The results are critical in building the knowledge base required to design 
nanoparticulate systems to be used safely and efficiently in delivery of lipophilic vitamins for 
food applications. Three objectives were identified.  
The first objective was to synthesize Chitosan/PLGA and PLGA particles with entrapped 
α-tocopherol (Figure 1.4) by emulsion evaporation method, and to characterize the particles with 
respect to morphology, size, size distribution, and zeta potential. Also, the effects of alpha-
tocopherol initial loadings, and chitosan concentration, on the particle size, size distribution and 
zeta potential were studied.  
The second objective was to investigate the stability of Chi/PLGA (αT) and PLGA (αT) 
particles as a function of pH and time. Size and zeta potential of αT emulsions, PLGA (αT), and 
Chi/PLGA (αT) as a function of pH were obtained over the pH range of 1-12. Morphology, size, 
KEY 
PLGA(αT) particles 
Chi/PLGA(αT) particles 
Free Vitamin 
Basal lamina 
Intestinal fluid 
Mucus 
iii) 
ii
) 
i) 
Figure 1.3 Schematic illustration of the mucus covered 
absorptive enterocytes  in the small intestine showing (i) 
the uptake of free vitamin via (ii) PLGA (αT) particle 
uptake, and (iii) mucoadhesive attachment of  Chi/PLGA 
(αT) retained at the intestinal brush border membrane (not 
to scale). 
8 
 
PDI and zeta potential were also studied over 24 hours, for Chi/PLGA (αT) and PLGA (αT) 
particles across different gastrointestinal pHs. 
The third objective was to measure the release profile of αT from Chi/PLGA (αT) and 
PLGA (αT) particles in simulated gastric and intestinal environment. The release rates were 
quantified and reported for Chi/PLGA (αT) at three different αT initial loadings, and for two 
types of system (PLGA (αT) versus Chi/PLGA (αT)), at physiological conditions for a period of 
2 and 7 days for gastric and intestinal environments, respectively. The gastrointestinal release 
profile was measured for 16% initial loading Chi/PLGA (αT) and PLGA (αT) under simulated 
GI fed and basal states. 
 
1.3 Components 
PLGA particles have been identified as superior delivery systems for lipophilic drugs 
(Birnbaum, Kosmala et al. 2000; Sahana, Mittal et al. 2008), due to their ability to shield the 
drugs from external harsh conditions that might lead to loss of activity and function (Sahana, 
Mittal et al. 2008). Entrapping αT in PLGA particles also tends to improve its solubility in 
aqueous media (Duclairoir 2002; Chen and Wagner 2004), but additional functionalization 
PLGA (αT) Chi/PLGA (αT) 
Chitosan 
Lecithin 
PLGA 
αT 
Colors symbolizing the 
different components 
Figure 1.4 Proposed PLGA and Chi/PLGA particle structure 
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would be required to slow down the transition through the alimentary canal. One way to achieve 
this is to promote the particles to adhere to the intestinal wall, by imparting positive charges to 
the particle surface by coating the particle with a cationic material, such as chitosan. Synthesis of 
Chitosan/PLGA particles requires the presence of a surfactant such as lecithin when 
emulsification processes are used. The three components selected for formation of the desired 
delivery systems, PLGA, chitosan, and lecithin are described below. 
1.3.1 PLGA 
Poly (D,L-Lactide-co-glycolide) (PLGA) (Figure 
1.5) is a common example of a synthetic polymer used in 
biological applications that is approved by the FDA as 
GRAS for pharmaceutical applications (Jalil and Nixon 
1990; Jain 2000). Its degradation is thought to occur mostly through hydrolysis, where it breaks 
down into its monomers, lactic acid and glycolic acids (Jalil and Nixon 1990; Cohen, Alonso et 
al. 1994; Jain 2000). The monomers, lactic acid and glycolic acids, are metabolized through the 
Kreb’s cycle and eliminated as harmless waste products, carbon dioxide and water (John M. 
Brady 1973; Tice and Cowsar 1984; Jalil and Nixon 1990; Jain 2000). Glycolic acid could also 
be excreted by the kidney in its primary form.  
PLGA degradation is dependent on a number of factors, such as pH, ionic strength of the 
environment, the mole ratio of the monomers, crystallinity of the polymer, additives, and 
temperature (Bala, Hariharan et al. 2004; Alexis 2005). Drug-loading affects the initial burst and 
the length of the lag phase. Dunne et al (2009) showed that an increase in drug-loading leads to a 
faster drug release. Drug-polymer interactions can also affect the degradation rate of the 
polymer, indirectly affecting the drug release rate  (Dunne, Ramtoola et al. 2009). Degradation 
mainly occurs by two mechanisms, via aqueous hydrolysis of the ester bonds and/or enzymatic 
Figure 1.5 Structure of PLGA 
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degradation (Giunchedi, Conti et al. 1998; Van Apeldoorn, Van Manen et al. 2004). The 
catalysis of PLGA degradation by the acidic oligomers, lactic and glycolic acids (Giunchedi, 
Conti et al. 1998), formed during random scission of the ester backbone is known as 
autocatalysis. Autocatalysis of PLGA microspheres increases the degradation rate with time 
(Mittal, Sahana et al. 2007; Zolnik and Burgess 2007). PLGA microspheres incubated at pH > 
pKa have a heterogenous pH within the microspheres resulting from pockets of acidic oligomers, 
causing a non-uniform degradation (Zolnik and Burgess 2007) where particle matrix and surface 
experience different rates of degradation. At pHs under the pKa, the PLGA particles experience a 
homogenous pH, the pH of the bulk media due to the by-product insolubility at very low pHs. 
The absorption of hydroxide ions from the media or the diffusion of the acidic by-products can 
lead to a suppression of the auto-catalysis effect, by preventing the acidic micro climate (Faisant, 
Siepmann et al. 2002).  
1.3.2 Chitosan 
Chitosan (Figure 1.6) is an N-deacetylated derivative of chitin, which is a naturally 
occurring basic polysaccharide. The degree of chitosan acetylation refers to the ratio of N-acety-
D-glucosamine units to the total number of chitosan units (Chatelet, Damour et al. 2001; Senel 
and McClure 2004). Chitosan is soluble in dilute acids but insoluble in water at neutral and 
alkaline pHs (Dutta, Viswanathan et al. 1997; Ravi Kumar 2000). Chitosan exists as a polycation 
at acidic pHs due to protonation of the amino groups, thus rendering the polymer hydrophilic and 
enables water retention at low pHs (Vachoud, Zydowicz et al. 2000; Senel and McClure 2004). 
Schipper et al (1996) studied the effect of molecular weight and degree of acetylation of chitosan 
in its ability to aid drug absorption. It was found that chitosan with low molecular weight and 
high degree of acetylation (≥ 35 %) did not help drug absorption while chitosan with low degree 
of acetylation and high molecular weight increased epithelial permeability (Schipper, Vårum et 
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al. 1996). The cell toxicity observed 
corresponded with the degree of 
acetylation, as well as a low charge 
density. For our purpose of drug delivery, 
chitosan of high molecular weight and low to intermediate degree of acetylation e.g. Protasan 
TM UP CL 213, ultrapure chitosan with ~ < 10−25 % acetylation and molecular weight of 
150−400 kDa (NovaMatrix) was appropriate to induce mucoadhesion and disbandment of the 
tight junction, with minimal or no toxicity.    
Intestinal mucoadhesion, a property characteristic to chitosan, is defined as the specific or 
the non-specific interactions between a component and the mucosal surfaces of the intestinal 
lining (Ponchel and Irache 1998). Mucin adsorption study of chitosan microspheres at different 
pHs, 1.5, 3.5 and 5.5, and ionic strengths, 0.2, 0.02, and 0.005, at 20 °C showed an increase in 
mucin adsorbed with pH rise and a decrease with increasing ionic strength (He, Davis et al. 
1998). Kawashima et al (2000) suggested that an electrostatic attraction between the negatively 
charged mucus layer of the intestine and the positively charged particle might be responsible for 
this mucoadhesive property of chitosan particles (Schipper, Vårum et al. 1996; Kawashima, 
Yamamoto et al. 2000). Interaction between the polymer entanglements and the mucus 
components increases the retention time of the chitosan particles in the GI tract (Kawashima, 
Yamamoto et al. 2000).  An in vitro study on the adsorption of mucin to chitosan microspheres 
with two types of mucin, whose sialic acid content varied, showed that charges played a major 
role in the mucoadhesivity; mucin with higher sialic acid content had greater zeta-potential, and 
in effect the most mucin-chitosan microsphere interactions (He, Davis et al. 1998). In vivo 
studies on the mucoadhesive property of chitosan were conducted by comparing mucoadhesivity 
and retention time of sub-micron sized liposomes (ss-Lip), chitosan coated sub micron sized 
Figure 1.6 Structure of chitosan 
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liposomes (ssCS-Lip) and chitosan coated liposomes (CS-Lip) in the intestinal tract of rats. 
Using confocal laser microscopy it was observed that the ssCS-Lip had the greatest retention 
time of all systems studied and as a result, the better mucoadhesive property. This behavior was 
attributed to the chitosan interactions as well as the small size of the system (Takeuchi, Matsui et 
al. 2005). The ssCS-Lip average particle size was 406 nm with a zeta potential of 30.3 mV in a 
pH of 4.4 (Takeuchi, Matsui et al. 2005). Besides its mucoadhesivity, chitosan bound to the 
epithelial cell membrane by a charge dependent mechanism was shown to result in an F-actin 
depolymerization and debandment of the tight junction protein ZO-1(Schipper, Olsson et al. 
1997). ZO-1 is a large cytosolic protein that is bound to the cytoskeleton proteins, actin fibers 
and occludin, which aids in stabilizing the interaction between the occludin molecules (Lodish 
2008).  The binding of the chitosan to the epithelial membrane increased the permeability of the 
apical membrane and tight junctions (Schipper, Olsson et al. 1997), resulting in an improved 
transport via the paracellular route.  
Kawashima et al (2000) reported that the size of nanoparticles formed by chitosan 
coating on PLGA nanoparticles varied between 264 nm and 15.2 µm depending on the 
concentration of chitosan, ranging from 0.20 to 0.50  w/v % (Kawashima, Yamamoto et al. 
2000). Hence, appropriate chitosan concentration needs to be elucidated for desired system. 
Chitosan has not yet been approved by the Food and Drug administration as GRAS for 
food applications. However, chitosan is believed to be appropriate for drug-delivery in biological 
systems, due to its high bio-absorbability, and its ability to degrade to non-toxic byproducts 
(Miyazaki, Ishii et al. 1981; Hou, Miyazaki et al. 1985; Ravi Kumar 2000).  In foods, chitosan 
polymers can be used as an antioxidant and antimicrobial agent (Rudrapatnam and Farooqahmed 
2003). Chitosan gives rise to highly viscous dietary fibers (Furda 1990), which are nontoxic and 
safe for consumption (Helsinki 1994). 
13 
 
1.3.3 Lecithin 
Lecithin is a biological anionic surfactant with phosphatidylcholine as the main 
component. It has a polar head group that is ionic, and two long hydrocarbon chains (Figure 1.7). 
Surfactants form micelles at low surfactant concentration, and the concentration at which point 
micelle formation begins is called the critical micelle concentration (CMC). The CMC of lecithin 
is 9 mM in aqueous solutions (Chain and Kemp 1934; Fischgold and Chain 1934) and ~ 0.1 and 
0.22 M in organic solutions (specifically hexane (Hancer, Patist et al. 2002). The hydrophilic − 
lipophilic balance (HLB) of lecithin is slightly lipophilic within a range of 4 − 8 (1 − 8 being a 
measure of lipophilicity, and 8 − 18 being hydrophilicity). The pH of lecithin is reported to range 
6.6 – 7.2 measured in the presence of 1 %  
ethanol aqueous solutions with an 
approximate isoelectric point (pI) at a pH 
of 3.5 (Bernard R. Bluestein and Clifford 
L. Hilton 1982). The phosphatides in the 
lecithin are positively charged below the pI 
of lecithin and zwitterionic above the pI 
(Chain and Kemp 1934; Fischgold and 
Chain 1934). Lecithin is an integral 
component of cell membranes (Shinoda, 
Shibata et al. 1993) and it is easily metabolized by the body. The United States FDA approved 
lecithin as a GRAS substance for use as a surfactant (USFDA/CFSAN 1979). Lecithin/chitosan 
nanoparticles smaller than 280 nm in size, with a zeta potential ~ 40 mV and a narrow size 
distribution of < 0.2 were reported by Sonvico et al (2006) (Sonvico, Cagnani et al. 2006). They 
reported that the interaction between chitosan and lecithin produced a more packed and denser 
Figure 1.7  Structure of lecithin 
(phosphatidylcholine) showing the hydrophilic 
head group and the lipophilic fatty acid tails. 
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structure (1.175 g/cm
3
) than lecithin alone (0.873 g/cm
3
) with chitosan located on the surface of 
the nanoparticles (Sonvico, Cagnani et al. 2006). Chitosan, a hydrophilic polymer, showed poor 
hydrophobic drug encapsulation efficiency as reported by Sonvico et al (2006) who loaded 
lecithin/chitosan particles with progesterone, a hydrophobic drug with low water solubility. A 
maximum drug loading efficiency as low as 3.5 % was achieved (Sonvico, Cagnani et al. 2006). 
Our proposed system, however, contains polymeric matrix of PLGA which has previously shown 
high lipophilic drug entrapment efficiencies (Zigoneanu, Astete et al. 2008). 
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Chapter 2 Chitosan/PLGA Particles for Oral Delivery of Lipophilic Model 
Vitamin (Alpha-tocopherol) in the Gastrointestinal Tract 
2.1 Introduction  
Vitamins are a class of nutrients essential for reproduction, repair, and growth and 
development of the human system (Packer, Slater et al. 1979; Mann, Nesheim et al. 1990; 
Combs 1998; Singh, Ye et al. 2009) that are not synthesized by the human body. Hence, vitamins 
required for daily functions are obtained from food, beverages, or supplements. There are two 
types of vitamins; the fat-soluble, such as vitamins A, D, E, K, and the water soluble vitamins, 
such as B and C vitamins. Vitamin E is a lipophilic antioxidant vitamin with properties that 
prevent cellular damage from chemical reactions that involve reactive oxygen species (ROS) 
(Halliwell 1999; Knight 2000; Young and Woodside 2001). Damage caused by ROS has been 
related to cancer (Zhang, Kramer et al. 1995), diabetes, cardiovascular disease (Kojda and 
Harrison 1999; Chisolm and Steinberg 2000; Adlam, Harrison et al. 2005), inflammatory 
responses, degenerative diseases (Vina, Lloret et al. 2004), aging (Ferrari 2004), liver injury 
(Vitaglione, Morisco et al. 2004), cataract (Taylor, Jacques et al. 1995), and others (Bergendi, 
Benes et al. 1999; Allen and Tresini 2000; Nishikawa, Edelstein et al. 2000). A balanced food 
intake rich in vitamins and antioxidants, including vitamin E, has been suggested to ensure 
optimal tissue levels of antioxidants (Lachance, Nakat et al. 2001) necessary to maintain a 
balance between ROS formation and antioxidant defense.   
Low mucosal permeability, low solubility of the compound in the mucosal fluids, 
premature elimination prior to complete absorption, and instability of the lipophilic vitamins in 
gastrointestinal environment, are some obstacles encountered with oral administration of 
lipophilic vitamins. On account of these limitations, the efficiency of absorption of vitamin E and 
16 
 
αT acetate, respectively, were reported to be approximately 36 % and 44 % in normal subjects 
(Klatskin and Molander 1952).  
Delivery systems were developed to address these obstacles, and improve the 
bioavailability of alpha-tocopherol (αT), the most bioactive form of vitamin E. For example, a 
study performed on horses showed that administration of αT in micellized form resulted in a 
higher αT plasma concentration compared to the vitamin delivered in its free form (Fiorellino, 
Lamprecht et al. 2009). In another study by Lipoid GmbH (Ludwigshafen, Germany), capsules 
made from purified phospholipids showed a 10 fold increase in αT absorption in blood plasma 
(Wajda, Zirkel et al. 2007). Although an increase in absorption was proven with the use of 
nanosized capsules with purified phospholipids, the maximum concentration attained was 
roughly 1.11 mg/L for an intake of 120 mg of vitamin E. The absorption efficiency was still low, 
less than 50 % of initial intake peaked at 6 hrs.  
Chitosan, an N-deacetylated, a derivative of chitin and a naturally occurring biopolymer 
with minimal toxicity that exhibits mucoadhesive properties, was identified as a potential 
component to increase GI transit time of vitamin and consequently its bioavailability. Various 
formulations of chitosan particles have been studied to promote sustained release of drugs both 
hydrophilic (Sajeesh, Bouchemal et al. ; Janes, Fresneau et al. 2001; Hu, Jiang et al. 2002) and 
hydrophobic (Calvo, Remuñán-López et al. 1997; Kosaraju, Weerakkody et al. 2009), to increase 
mucoadhesion (Kockisch, Rees et al. 2005; Wei, Wang et al. 2008), for drug targeting (Park, 
Saravanakumar et al.), and pH sensitive drug delivery (Hu, Jiang et al. 2002; Sipahigil, Gürsoy et 
al. 2006), DNA transfection (Lavertu, Méthot et al. 2006; Bowman, Sarkar et al. 2008; Lai and 
Lin 2009), protein protection and delivery (Amet, Wang et al. ; Lameiro, Lopes et al. 2006; 
Rekha and Sharma 2009; Sonaje, Lin et al. 2009), increased absorption and uptake (Florea, 
Thanou et al. 2006; Zhang, Zhang et al. 2008), as well as for vaccination (Chew, Wolfowicz et 
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al. 2003; van der Lubben, Kersten et al. 2003; Borges, Borchard et al. 2005; Borges, Cordeiro-
da-Silva et al. 2006; Rajesh Kumar, Ishaq Ahmed et al. 2008; Tian, Yu et al. 2008). Chitosan 
based particles were also used to delay gastric emptying (Soane, Frier et al. 1999; Torrado, Prada 
et al. 2004).   
Interactions between the polymer entanglements and the mucus components increased 
retention time of chitosan or chitosan-coated particles in the GI tract (Ponchel and Irache 1998; 
Kawashima, Yamamoto et al. 2000). Kawashima et al (2000) reported that chitosan coated 
PLGA particles were able to achieve longer intestinal retention by penetrating into the deeper 
mucus layer and attaching to the mucus tissue (Kawashima, Yamamoto et al. 2000). A vast array 
of studies have been performed to utilize and harness the merits of chitosan for oral delivery, 
however, detailed knowledge of the biocompatible polymeric system capable of both controlled 
release, mucoadhesion, and pH responsiveness to increase the gastrointestinal transit of 
lipophilic vitamins are still lacking. The purpose of this project was to investigate the in vitro 
gastrointestinal stability of a nanoparticulate system formed of chitosan and PLGA stabilized by 
lecithin, and the release behavior of lipophilic bioactives, specifically αT from this system under 
fasted and fed state physiological conditions. The thrust of this research was to understand the 
mechanisms involved in GI delivery of αT with a particular delivery system, Chi/PLGA. The 
results are critical in building the knowledge base required to design nanoparticulate systems to 
be used safely and efficiently in delivery of lipophilic vitamins for food applications. 
2.2 Materials  
Chitosan with an average molecular weight of 150 − 400 kDa and 70 – 90 % degree of 
deacetylation was obtained from NovaMatrix Ultrapure Polymer Systems Inc. (Sandvika, 
Norway), PLGA (50:50) with an average molecular weight of 40,000 – 75,000, D,L- alpha 
tocopherol (97 %), sodium taurocholate, D (+) − trehalose dihydrate, sodium acetate, and sodium 
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chloride were purchased from Sigma Aldrich (Saint Louis, MO, USA). Soybean lecithin, glacial 
acetic acid, hydrochloric acid, sodium hydroxide, monobasic and dibasic sodium phosphate, and 
potassium chloride were purchased from Fischer Scientific (Fair Lawn, NJ, USA).  Ethyl acetate, 
acetonitrile, methanol, anhydrous sodium acetate, and isopropanol were obtained from EMD 
Chemicals Inc. (Gibbstown, NJ, USA). Nanopure water was obtained using Nanopure Diamond 
(Barnstead international, Dubuque, IA, USA). 100 kDa Cellulose Ester biotech membrane tubing 
and closures were obtained from Spectrum Laboratories Inc. (Rancho Dominguez, CA, USA). 
2.3 Methods 
2.3.1 Synthesis of PLGA and Chitosan/PLGA Particles with Entrapped Alpha-tocopherol 
PLGA and Chi/PLGA particles with entrapped αT were synthesized by emulsion-
evaporation using a slightly modified method outlined in Astete and Sabliov (2006) (Figure 2.1). 
Initially, an organic phase was formed with 2 w/v % PLGA and αT dissolved in ethyl acetate at 
three different initial loading concentrations (8 %, 16 %, and 24 % w/w relative to PLGA mass). 
An aqueous phase was formed with 11 mM lecithin (20 % > CMC = 9 mM (Hodgson and 
Wakeman 2005) dissolved in ethyl−acetate saturated water. The organic phase was added in 
drops to the aqueous phase at oil to water ratio of 1:4, in an ice bath, under continuous 
sonication. The sample was sonicated for 1 min at 750 W, and 40 % amplitude using a probe-
type sonicator (VC505, Sonics and Materials Inc. Newton, CT, USA). Next, the organic solvent, 
ethyl-acetate, was evaporated under vacuum, at approximately 500 − 600 mmHg and nitrogen 
injection (80 mmHg), in a rotovapor (Buchi R-124, Buchi Analytical Inc. New Castle, DE, 
USA). PLGA (αT) nanoparticles were produced following complete evaporation of ethyl acetate.  
Next, the PLGA (αT) nanoparticle suspension was added to a 0.01 w/v % chitosan solution in 
drops under continuous sonication. For the chitosan concentration study, the volume of chitosan 
solutions was varied to obtain a final chitosan concentration ranging between 0 − 0.625 mg/mL. 
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The complex was sonicated in pulse-mode for 10 minutes with a duty cycle of 2s to form 
dispersed Chi/PLGA (αT) particle system. Final nanoparticle suspension was washed by dialysis 
using a100kDa Spectra/POR CE membrane (Spectrum Rancho, Dominquez, CA) to remove un-
entrapped αT and excess surfactant. The suspension was placed in the membrane and suspended 
in 1.5 L nanopure water for 24 hours. The dialysis medium was changed every 8 hours. The 
particles were then lyophilized using a FreeZone 2.5 Plus (Labconco, Kansas City, MO, USA) at 
−80 °C with a trehalose to particle ratio of 1:4 for 48 hours. 
 
2.3.2 Size, Size Distribution, and Zeta Potential Measurement 
Size, polydispersity index (PDI) and zeta-potential were measured by dynamic light 
scattering using the Malvern Zetasizer Nano ZS (Malvern Instruments Inc., Southborough, MA).  
Size and PDI measurements were obtained for particles after re-suspension, in triplicate.  A 
volume of 1.3 ml of each sample at a concentration of 0.3 mg/ml was placed in a polystyrene 
Drop-wise addition of 
organic phase into the 
aqueous phase #1 
Drop-wise addition of PLGA 
NPs into aqueous phase  #2 
Evaporation of 
organic solvent 
Sonication 
Pulsed 
sonication 
Continuous 
sonication 
Final particle 
(not to scale) 
Lyophilization 
Dialysis 
Figure 2.1  Particle synthesis procedure 
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cuvette and measured at 25ºC. The mean values of size and PDI was determined using a mono-
modal distribution. 
 2.3.3 Morphology 
The morphology of the nanoparticles was studied by Transmission Electron Microscopy 
(TEM) using a JEOL 100-CX (JEOL USA Inc., Peabody, MA) system. One droplet of the 
nanoparticle suspension was placed on a copper grid of 400 mesh with a carbon film, and the 
excess sample was removed with filter paper. Uranium acetate 2 % was used as a stain; the 
excess uranium acetate was removed after 1 min with filter paper. The sample was dried before 
analysis by TEM. 
2.3.4 Entrapment Efficiency 
Entrapment efficiency of αT in particles was determined by dissolving a mass of 
lyophilized particles equivalent to 0.002 w/v% theoretical amount of αT in 95:5 (v/v %) 
acetonitrile : H2O under sonication for 15 seconds, followed by incubation for 2 hrs. The sample 
was centrifuged at 30,000 rpm for 1 hour with an Allegra 64R centrifuge (Beckman Coulter, 
Fullerton, CA, USA), and the supernatant was injected in the HPLC for quantification of the 
entrapped vitamin.  
A standard curve, with a linear dynamic range of 0 − 580 ng/ µL for αT in 95/5 
acetonitrile to H2O, was generated and used to convert the area under curve to αT concentration. 
αT entrapment efficiency was calculated by dividing the mass of αT detected experimentally by 
that expected theoretically at the 3 initial loadings studied, 8, 16, and 24 % (CP8, CP16, and 
CP24). Chi/PLGA particles showed no significant change in entrapment efficiency with initial 
loading. Average entrapment efficiency of 49 ± 3.6 %, 55 ± 8.6 %, and 53 ± 6.4 % were 
measured for 8 %, 16 %, and 24 % initial loadings, respectively. The individual entrapment 
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efficiency values at each initial loading were used to quantify the release of αT under 
gastrointestinal conditions. 
2.3.5 Stability of Particles 
The pH stability of αT emulsions, PLGA (αT), and Chi/PLGA (αT) particles was studied 
over a pH range of 1-12. Particles were suspended in pH adjusted nanopure water and pH 
titrations were carried out, while simultaneously obtaining the size, PDI, and zeta-potential using 
the Malvern Zetasizer Nano ZS/MPT-2 (Malvern Instruments Inc., Southborough, MA). Dilute 
HCl and NaOH solutions were used for pH adjustments. 
The time dependent pH stability of particles was studied under gastric basal (pH 1.5) and 
fed (pH 4.0), as well as intestinal basal (pH 6.5) and fed (pH 5.5) pHs. Particles were suspended 
in pH buffers, at each time interval, 0, 3, 6, and 24 hrs, an aliquot was sampled using the 
Malvern Zetasizer Nano ZS (Malvern Instruments Inc., Southborough, MA) for particle size, 
PDI, and zeta-potential, while morphology was obtained using a JEOL 100-CX (JEOL USA Inc., 
Peabody, MA). 
2.3.6 Gastrointestinal Release Profiles of Alpha-tocopherol from Chitosan/PLGA 
Particles 
The in vitro release profiles of the Chitosan/PLGA particles were studied under simulated 
gastric and intestinal environments for fasted and fed conditions (Shakweh, Besnard et al. 2005; 
Brouwers, Tack et al. 2007). The simulated intestinal fluid consisted of 3 mM sodium 
taurocholate and 0.75 mM lecithin dissolved in phosphate buffer solution, at pH 6.5 and 5.5, 
basal and fed pHs respectively. The simulated gastric fluid consisted of 2.0 g of NaCl dissolved 
in 7.0 ml of 1 M HCl, diluted to a final volume of 1L using nanopure water, and pH adjusted to 
1.5 and 4.0, the basal and fed gastric pHs respectively.  
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To measure release, lyophilized particles equivalent to 0.002 w/v% theoretical amount of 
αT were re-suspended in 15 ml of the respective media, and spilt into 14 aliquots. All samples 
were placed in a C25KC incubator shaker (New Brunswick Scientific, Edison, NJ, USA) at 37 
°C and 100 rpm, over a time span of 2 and 7 days for gastric and intestinal sampling, 
respectively. At each time interval, an aliquot sample was centrifuged at 30,000 rpm for 1 hour 
with an Allegra 64R centrifuge (Beckman Coulter, Fullerton, CA, USA). The pellet was briefly 
rinsed with nanopure water to remove residual salts from the media, and then it was dissolved in 
95:5 v/v % acetonitrile : H2O following the entrapment efficiency procedure outlined above, to 
quantify the αT by HPLC.  
2.3.7 HPLC Quantification 
The supernatant containing the dissolved αT was quantified using reverse-phase high 
performance liquid chromatography. The HPLC system consisted of 1200 series Agilent vacuum 
degasser, binary pump with sample mixing, standard auto-sampler, thermostatted column 
compartment containing the reverse-phase column, diode-array and fluorescence detectors (1200 
series Agilent System, Agilent Technologies, Santa Clara, CA, USA), all connected in series. 
Isocratic elution at room temperature was utilized with 95:5 v/v % methanol to water as the 
mobile phase. 25 µl of sample was automatically injected at a flow rate of 0.5 ml/min through a 
Zorbax Eclipse-XDB C18 3.0 x 100 mm, 3.5 µm (Agilent Technologies Inc. Santa Clara, CA, 
USA). The 1200 series fluorescence detector (Agilent Technologies Inc. Santa Clara, CA, USA) 
at excitation and emission wavelengths of 290 nm and 320 nm, respectively, was utilized for αT 
detection.  
2.3.8 Statistical Analysis 
One way analysis of variance with Tukey adjustment was used to analyze the chitosan 
effect on particle size and zeta potential. Two factor ANOVA was used to estimate the 
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significant difference in size, PDI, and zeta-potential between PLGA and Chitosan/PLGA 
particles for different αT initial loadings, and also for differences associated with pH stability. 
Data is presented as mean ± standard error of the mean, having been measured at least in 
triplicate. A difference between the means was considered significant if the p-value was less than 
or equal to 0.05. All statistical analyses were run in SAS
®
 (SAS Institute Inc., Cary, NC, USA). 
2.4  Results and Discussion 
2.4.1 Effect of Chitosan Concentration on Size and Zeta Potential of Chitosan/PLGA Particles 
The effect of chitosan concentration on Chi/PLGA particles was studied for chitosan 
concentrations ranging between 0 to 0.625 mg/mL; this study was required to find the optimum 
chitosan concentration that would yield stable, positively charged particles. Three regions were 
observed (Figure 2.2). In Region I (chitosan between 0 to 0.2 mg/mL), stable particles with an 
average hydrodynamic diameter of 126 nm and surface potential of − 43 mV were synthesized, 
with no significant change in particle properties with chitosan concentration. TEM images of 
particles obtained at 0 mg/mL chitosan (PLGA particles) showed spherical, well-dispersed 
particles (Figure 2.2b). Chi/PLGA particles within Region II (0.2 to 0.35 mg/mL chitosan) were 
unstable and had a tendency to precipitate within minutes of formation. Zeta-potential of these 
particles ranged between −30 to +30 mV, while the average particle diameter ranged between 1.5 
to 8.1 μm. Stable polydisperse particles of 283 nm and positive potential of +56 mV were 
observed in Region III (Figure 2.2a). No significant change in size or zeta-potential was 
observed for particles in this concentration range (0.35 to 0.625 mg/mL) with an increase in 
chitosan concentration. TEM image of particles at 0.6 mg/mL chitosan concentration showed 
spherical particles with wide size distribution (Figure 2.2c). The particle properties of Chi/PLGA 
particles stabilized by lecithin followed a similar trend as those stabilized by PVA reported by 
Nafee et al (2007); the difference was that Chi/PLGA/lecithin particles synthesized herein 
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indicated a positive potential at 0.3 mg/mL of chitosan, whereas Chi/PLGA/PVA required only 
0.2 mg/mL for a positive zeta potential (Nafee, Taetz et al. 2007), as expected due to the 
presence of lecithin.  
 
Figure 2.2 a) Average hydrodynamic diameter and zeta potential of Chi/PLGA particles 
synthesized at a final chitosan concentration ranging between 0 − 0.625 mg/mL, n = 3. TEM 
images at 10K magnification are inserted to show, b) PLGA particles (0 mg/mL chitosan), and c) 
Chi/PLGA particles (0.6 mg/mL chitosan). 
In formation of Chi/PLGA/lecithin particles, the electrostatic interaction of the amine 
groups of chitosan with the phosphate groups of lecithin allowed for chitosan to deposit as layers 
on the PLGA particle surface to produce Chi/PLGA particles, increasing zeta-potential of 
particles. It was observed that an increase in chitosan concentration increased the surface 
potential for final chitosan concentrations up to 0.4 mg/mL chitosan, above which zeta-potential 
showed no significant change with increasing chitosan concentrations (Figure 2.2a). This was 
mostly due to the saturation of the number of units that can adhere onto the surface of PLGA 
particles due to the electrostatic interaction with lecithin. Above this limit, excess chitosan is 
either held on by chain entanglement by association, or as free units in suspension. 
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Purification of the polymers and surfactant prior to particle synthesis would decrease the 
variability between experimental sets, but in turn add to the cost of the process due to the 
addition of extra processing steps. Hence, for this study all components were used as obtained 
from the chemical company without further processing. Standard error of mean between 
experimental sets varied largely due to the use of polymers of varying molecular weights. Stable, 
positively charged particles were synthesized at chitosan concentrations exceeding 0.4 mg/mL. 
The positive charge is necessary for mucoadhesive attachment by electrostatic interaction of the 
particles to the negatively charged glycocalyx groups of the mucin on the intestinal walls (He, 
Davis et al. 1998). Hence, all particles used in the follow up studies were prepared at a final 
chitosan concentration of 0.6 mg/mL. 
 
Figure 2.3 Effect of polymer and αT initial loading on a) size, b) PDI (dashed line) and zeta-
potential (solid line) of PLGA and Chi/PLGA particles 
2.4.2 Effect of Alpha-tocopherol Initial loading on Chitosan/PLGA and PLGA Particle 
Size, Size Distribution, and Surface Potential 
The effect of αT loading on particle size, PDI, and zeta-potential was studied for both 
PLGA and Chi/PLGA particles at three αT initial loadings, 8, 16, and 24 %, with respect to the 
PLGA mass to determine if changes in drug loading altered the particle properties. Both particle 
systems, PLGA and Chi/PLGA, showed no significant change in size, PDI, or zeta-potential with 
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increasing initial loading of αT between 0 to 24 %. PLGA particles had an average particle size, 
PDI, and zeta-potential of 84 nm, 0.195 and −55 mV, respectively, while Chi/PLGA particles 
measured 333 nm, with a PDI of 0.279, and zeta potential of +58 mV, across loadings  (Figure 
2.3).  
Although initial loading had no effect on the particle properties, the addition of chitosan 
to PLGA showed a significant effect on particle size, PDI, and potential, as shown in previous 
studies with Chi/PLGA particles (Nafee, Taetz et al. 2007) and Chi-lecithin nanospheres 
(Ogawa, Decker et al. 2003; Sonvico, Cagnani et al. 2006). The size of PLGA particles increased 
from 84 nm to 333 nm by the addition of chitosan (Figure 2.3a), accompanied by a potential shift 
from −55 mV to +58 mV (Figure 2.3b). From the above findings, increase in αT loading would 
not affect the particle properties, hence higher drug-loadings could be utilized while still 
maintaining similar particle size and potential. This also ensured that αT release kinetics from 
PLGA or Chi/PLGA particles would not be affected by particle size or potential with increasing 
αT loadings. 
2.4.3 Stability of Chitosan/PLGA and PLGA Particles as a Function of pH and Time 
Knowledge of the particle stability was important to decipher the αT release kinetics from 
PLGA and Chi/PLGA particles under gastrointestinal conditions. The GI tract is a dynamic 
environment wherein pH changes with time; hence the change in particle properties as pH 
changes over time was studied. The stomach maintains a low pH of approximately 1.5, 
characterized by high concentrations of hydrochloric acid, but when eating the pH of the 
stomach jumps to 5 when the fluids (around pH 7.4) from the mouth reach the stomach. The pH 
of the stomach returns to the basal pH of 1.5 gradually over 2 – 4 hrs time, with an average pH of 
4.0. Gastric emptying occurs during this time. About 50 % of the ingested material is emptied 
into the small intestine at 2 hrs and approximately 100 % emptied around 4 hrs (Russell, Berardi 
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et al. 1993). Therefore, it was assumed that the lipophilic vitamin entrapped in a given particulate 
system would experience a pH of 1.5 and pHs below 5 for at least 2 hrs, before moving onto the 
intestinal conditions. Similarly the intestine maintains a pH of 6.5 under fasting and drops to a 
pH 5.5 as material from the stomach is emptied into the small intestine. The pH then gradually 
returns to pH 6.5 (in the ileum) as food transitions to the large intestine at neutral pHs.  
Hence, stability of the particles and the intestinal release of αT from the particles under fed 
conditions were simulated for the stomach at pHs 1.5 and 4.0 (basal and fed states) and small 
intestine at pH 5.5, and at pH 6.5 for fasted state. 
The stability study across pH showed that αT emulsions made with lecithin and PLGA 
(αT) particles approached zero potential, with an average zeta-potential of −15 mV and −5 mV 
respectively (Figure 2.4a, Table 2.1) at pH 2.0.The particles and emulsion droplets edged 
towards aggregation as the pH was decreased below 3, with an average diameter of 178 nm and 
332 nm, respectively (Figure 2.4b). In comparison, Chi/PLGA particles were stable below pH 
5.5 and above pH 8, but particle aggregation occurred between pH 5 and 8 (Figure 2.4). This 
phenomenon was not reversible. A gradual increase in pH from 1.5 resulted in particle 
aggregation around 5.5, and a decrease in pH from 12 resulted in aggregation at pH 7. Particle 
aggregation around pH 6 for chitosan particles, with a charge inversion from negative to positive 
around this pH was expected from previous findings (Ogawa, Decker et al. 2003) and each 
component’s position of pKa on the pH scale (Table 2.1). The Chi/PLGA particles exhibited a 
positive charge of ~ 40 mV below pH 5 and a negative charge of ~ − 50 mV above pH 8; the 
corresponding particle diameters were approximately 381 nm below pH 5 and 301 nm above pH 
8. This indicated that although the unbound surface amine groups of chitosan were deprotonated, 
the negative charge from PLGA and lecithin (Table 2.1) offered sufficient potential to prevent 
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the particles from aggregation at pHs above 8. Also, Chi/PLGA particles above pH 8 were 
significantly greater in size in comparison to PLGA particles (Figure 2.4b), indicating that the 
chitosan layer bound to the particles was still present. Chi/PLGA particles below pH 5.5 
remained positively charged and stable due to the protonation of the surface amine moieties of 
chitosan (Table 2.1), conferring sufficient potential to stabilize and disperse the particle system 
at low pHs.  
 
Figure 2.4 Stability of αT emulsions, PLGA (αT), and Chi/PLGA (αT) particles as a function of 
pH, characterized by changes in a) surface potential and b) average particle size. pH at which 
precipitation of Chi/PLGA particles was observed is indicated by the shaded region. 
Table 2.1 Charge distribution of αT emulsions, PLGA (αT) and Chi/PLGA (αT) particles and 
their individual components, poly (D, L-lactide-co-glycolide), chitosan, and lecithin across the 
pH scale, highlighting their respective point of zero charge (p.z.c.) 
 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 
PLGA
*
 0 0 0      
Chitosan
†
 + + + + + 0 0 0 
Lecithin
‡
 + 0 ± ± ± ± ± ± 
αT/ Lecithin¥         
PLGA/Lecithin
¥ 
        
Chi/PLGA/Lecithin
¥
 + + + + 0    
* (Sober 1918), † (Liu, Sun et al. 2005), ‡ (Chain and Kemp 1934; Fischgold and Chain 1934), ¥ 
obtained from Figure 3 
The pH stability clearly indicated that Chi/PLGA particles aggregate around basal 
intestinal conditions, while PLGA particles aggregate around basal gastric conditions, a 
significant fact to consider for GI delivery. PLGA particle properties were reversible when pH 
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was increased from gastric to intestinal pHs with a slight increase in size, but Chi/PLGA 
particles were not revived to original condition after aggregation. Chi/PLGA particles lose the 
positive charge with aggregation, which would affect the mucoadhesive capacity of the particles 
as particles transition towards the distal ileum, which primarily maintains a neutral pH.  
Stability of PLGA and Chi/PLGA particles exposed to gastric (pH basal  ~ 1.5 and pH fed  ~ 
4.0) and intestinal (pH basal  ~ 6.5 and pH fed  ~ 5.5)  conditions was studied over time ( Figure 
2.5). As expected, based on the pH stability study (Figure 2.4) PLGA particles precipitated in pH 
1.5, making it difficult to obtain particle property values. Particle morphology observed with 
TEM confirmed that aggregation at this pH occurred instantaneously (Figure 2.6a). PLGA 
particles re-suspended in pHs 4.0, 5.5, and 6.5 buffer and remained stable for 24 hours, with no 
significant change in average size (123 nm), PDI (0.234), or zeta-potential (−28 mV) over time 
(Figure 2.5). TEM imaging showed that at pH 4.0 particles aggregated less and individual 
particle structures were visibly discernable (Figure 2.6b), compared to particles at pH 1.5 (Figure 
2.6a). At pH 5.5 and 6.5, stable individual particles were identified (Figures 2.6c & d), thus 
corroborating the quantitative results that PLGA particles were stable in pH 5.5 and 6.5 for 24 
hours obtained by dynamic light scattering.  
Chi/PLGA particles re-suspended in pH 1.5 and 4.0 buffers remained stable for 24 hours 
with no significant change in size (345 nm), PDI (0.415), or zeta-potential (+30 mV) (Figure 
2.5). TEM imaging (Figures 2.6e & f) showed well dispersed and spherical particles at these 
pHs. At pH 5.5 Chi/PLGA particles started out dispersed but tended towards aggregation with 
time (phenomenon observed after 6 hrs at this pH), while aggregation was observed instantly at 
pH 6.5 (Figure 2.6g & h). The immediate aggregation of Chi/PLGA particles at pH 6.5, showed 
no change with time (Figure 2.6h). Particle size, PDI, and zeta-potential are not available at pH 
6.5 for the Chi/PLGA system due to the instability of the particles at this pH. The solubility of 
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Chi/PLGA particles at acidic pHs 1.5 can be explained by protonation of the amine groups at this 
pH (Table 2.1) which produced sufficient charge interaction to solvate and stabilize the particles. 
At higher pHs, especially at those approaching chitosan pKa, zeta-potential of chitosan particles 
approaches neutral (Table 2.1), and particles tended to aggregate (Sonvico, Cagnani et al. 2006). 
The pH at which aggregation begins depends on the specific particle system. In comparison to 
our system, Chitosan-PLGA particles stabilized by PVA showed zero potential close to pH 4.0 
(Kawashima, Yamamoto et al. 2000), while chitosan-lecithin emulsions aggregated at pH 6.0 
(Sonvico, Cagnani et al. 2006).  
 
Figure 2.5 Stability of  PLGA (αT) (filled) and Chi/PLGA (αT) (empty) particles as a function 
of time and pH; observations were made for 24 hrs at 37 °C, under 4 different pHs – 1.5, 4.0, 5.5 
and 6.5. * significantly different (p < 0.05) 
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Figure 2.6 TEM images of PLGA particles under a) gastric fasted state pH of 1.5 over 2 hrs at a magnification of 33K, b) gastric fed 
state pH of 4.0 over 2 hrs at a magnification of 33K, c) intestinal fasted state pH of 6.5 over 24 hrs at a magnification of 33K, d) 
intestinal fed state pH of 5.5 over 24 hrs at a magnification of 33K; and Chi/PLGA particles under e) gastric fasted state pH of 1.5 
over 2 hrs at a magnification of 100K, f) gastric fed state pH of 4.0 over 2 hrs at a magnification of 100K, g) intestinal fasted state pH 
of 6.5 over 24 hrs at a magnification of 20K and 33K, and h) intestinal fed state pH of 5.5 over 24 hrs at a magnification of 33K  
h 
g 
0 hrs 6 hrs 24 hrs 
0 hrs 6 hrs 24 hrs 
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Although Chi/PLGA particle aggregation occurs after 6 hours when exposed to pH 5.5, 
particles still exhibited a positive potential at this pH (Figure 2.5). Furthermore, chitosan was 
proven to remain adhered to the PLGA particles at high pHs, as indicated by the particle size. 
Therefore, this indicated that if particle attachment occurred at the beginning of the intestinal 
loop, where gastric dilution renders the fluid slightly acidic, then amine groups of Chi/PLGA 
particles already attached to the surface would be unaffected by the change in pH, thus remain 
attached until mucus turnover occurs, 3 to 5 days later. This would ensure a timed released of the 
entrapped αT, prior to excretion. 
2.4.4 Controlled Release of Alpha-tocopherol from Chitosan/PLGA and PLGA Particles 
in Simulated Gastrointestinal Environment 
The impact of two factors, initial loading (8, 16, and 24 %) and the type of system 
(PLGA versus Chi/PLGA), on αT release was studied at physicochemical conditions to predict 
the release behavior of αT from the particles in a human gastrointestinal tract. 
2.4.4.1 The Effect of Alpha-tocopherol Initial Loading on Alpha-tocopherol Release from 
Chi/PLGA Particles under Gastrointestinal Conditions  
αT initial loading (8, 16, and 24 %) had a significant effect on the αT release profile 
under the basal gastric conditions (pH 1.5, 37 °C, and 150 rpm). Significantly faster αT release 
was observed for CP8 particles, with 24 % of αT released instantaneously, and 46 % released 
after 2 hrs; whereas CP16 and CP24 particles showed no significant difference in release 
between each other. CP16 and CP24 particle formulations had an instant αT release of only 11 % 
and 12 %, and 30 % and 21 % after 2 hrs, respectively (Figure 2.7a). Chi/PLGA particles for all 
three initial loadings, 8 %, 16 %, and 24 %, had no significant difference in size (Figure 2.3a).  
Therefore, the location of the vitamin as opposed to particle size affected the diffusion rate of 
αT. αT has an alcohol group bound to the chromanol ring offering the molecule some 
hydrophilicity, though not strong enough to solubilize the vitamin in aqueous media, it aids the 
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molecule orient itself within the oil−water interface, thus, acting as a co-surfactant. Due to this 
reason, αT molecules initially align around the PLGA-lecithin interface, until surface became 
saturated and additional αT molecules were pushed within the matrix due to steric interactions. 
Vitamin located at the surface released initially followed by the gradual release of the vitamin 
from within the particle matrix, giving rise to a biphasic release profile, with approximately 
100% of the vitamin released in 2 days (Figure 2.7b). 
On the other hand, the intestinal release of αT from Chi/PLGA particles at different initial 
loadings showed no significant difference in release, with an average initial release of 3 ± 2% for 
all three loadings at time zero, and an maximum average release of 81 ± 6 %, 58 ± 12 %, and 83 
± 5 % for CP8, CP16, and CP24, respectively, over a 5 day period (Figure 2.8). The difference in 
media constitution was suspected to have caused the comparable αT burst release between the 3 
initial loadings under intestinal conditions, while a disparity was observed across loadings under 
gastric conditions. The presence of solubilizing agents in the simulated intestinal media, 
including lecithin and bile salts, promoted αT solubility in the surrounding media, which in turn 
led to a concentration driven diffusion of αT from the particles. In contrast, the absence of 
solubility enhancers in the gastric environment delayed the vitamin release until sufficient 
molecules of vitamin were released and in close proximity to form transport vehicles by 
association with each other (with the hydrophilic chromanol side of the tocopherol facing the 
aqueous media, while the hydrophobic fatty tails oriented towards the center). Hence, while no 
difference was observed in the intestinal, initial loading affected the gastric release of the 
vitamin.  
After 24 hours, an average gastric αT release of 91%, 73% and 66% was observed for 
CP8, CP16, and CP24 particle formulations, respectively (Figure 2.7b). As a result of minimal 
initial release and slower release rate over 2 hours (preferred in drug delivery), αT initial 
37 
 
loadings greater than 8 % was preferred for lipophilic vitamin gastrointestinal delivery. Higher 
initial loadings were necessary to ensure minimal αT release in the stomach before reaching the 
intestine, where majority of the lipophilic compound absorption would occur; Chi/PLGA with 16 
% initial loading exhibited a 50 − 80 % αT release over 5 days under intestinal conditions. 
Therefore, Chi/PLGA particles at 16 % initial loading were selected o study the effect of system 
on αT release in the GI tract. 
 
Figure 2.7 Gastric release of αT from Chi/PLGA particles at 3 initial loadings (8, 16, and 24 %) 
under basal stomach conditions over a) 3 hrs and b) 48 hours. 
2.4.4.2 The Effect of Particle System, PLGA and Chi/PLGA, on Alpha-tocopherol Release 
from Particles under Gastrointestinal Conditions 
 The release of αT from the particles was expected to be dependent not only on vitamin 
diffusion but also on particle characteristics. The physicochemical properties of the PLGA and 
Chi/PLGA particles were investigated in the previous sections to understand the differences in 
αT release from these two systems. Time and pH dependent stability profile (Figures 2.4 & 2.5) 
showed that PLGA particles aggregated and clumped out of solution, at pH 1.5, whereas 
Chi/PLGA particles were well-dispersed. 
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Theoretically, delayed αT release was 
expected from PLGA particles due to 
particle aggregation. However, PLGA 
particles had a faster release of 24 % 
and 59 %, at time 0 and 2 hrs, 
respectively, when compared to 
Chi/PLGA particles which released only 
11 % and 30 % αT at 0 and 2 hrs, 
respectively, under basal gastric 
conditions (pH 1.5). Under fed gastric 
conditions (pH 4.0), 22 % and 40 % αT was released from PLGA particles as compared to 12 % 
and 20 % αT released from Chi/PLGA particles (Figure 2.9). After 6 hrs 66 ± 12 %, and 49 ± 10 
% αT was released from PLGA and Chi/PLGA particles, respectively (Figure 2.9a). Statically, 
no significant difference in αT release was observed between the fed and basal gastric pHs, 
indicating that PLGA particle aggregation at pH 1.5 did not affect the release rate of vitamin 
which was similar to αT release under fed gastric pH of 4.0. TEM images supported aggregation 
at low pHs (Figures 2.6a & b) for PLGA particles but coalescence was not visible; thus, PLGA 
particles lacked the sufficient charge to be uniformly dispersed in the media and precipitated 
while still maintaining the spherical nature of the particles with minimum effect on release. 
However, the amount of αT released varied significantly based on the particle system (PLGA 
versus Chi/PLGA). Smaller PLGA particles released αT faster than Chi/PLGA particles, 
especially under short time spans, while protonation of the chitosan amine groups over time, 
approximately 6 hrs under gastric conditions, led to the extension of the chitosan chains on the 
surface; thus, essentially rendering the Chi/PLGA particles to behave like PLGA particles. 
Figure 2.8 Intestinal release of αT from Chi/PLGA at 
3 αT intial loadings (8, 16, and 24 %) particles under 
basal conditions. 
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Without the added protection of the outer layer, to delay the diffusion of αT, αT release rate from 
Chi/PLGA particles after 6 hrs mirrored PLGA particles, under gastric conditions.  
αT release from PLGA and Chi/PLGA particles under intestinal basal (pH 6.5) and fed 
(pH 5.5) conditions showed that statistically the release did not differ between basal and fed 
conditions, similar to release under gastric fed and basal states, however a significant change in 
release was observed between particle systems, and as a function of time (Figure 2.9b). Initially, 
PLGA particles released 19 % and 29 %, whereas Chi/PLGA particles released only 9 % and 7 
% αT, in pH 5.5 and 6.5, fed and basal intestinal pHs respectively. PLGA particles showed a 
higher burst release of αT compared to Chi/PLGA particles. Though, αT released from PLGA 
particles after 5 days seemed to vary, 54 % under basal (pH 6.5) and 82 % under fed (pH 5.5) 
intestinal pHs, the amount released did not differ statistically. 
 
Figure 2.9 Release of αT from PLGA and Chi/PLGA particles at basal (solid line) and fed 
(dashed line) a) gastric, and b) intestinal conditions. 
Chi/PLGA particles were approximately 4 times bigger than PLGA particles at pH 4.0 
and 5.5, fed gastric and intestinal conditions. The significant size difference between both 
particle systems, under fed conditions, was responsible for the higher initial αT release from 
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PLGA particles. Diffusion rate of solutes and solvents to and from the particle depends on the 
surface area to volume ratio of the particles, and it was expected that larger particles would 
exhibit slower release time while smaller particles would comparably have faster release, 
phenomenon observed herein.  
It was noticed that under both basal and fed conditions the Chi/PLGA particles released 
approximately half as much as the PLGA particles, under gastric conditions. This is beneficial to 
lipophilic bioactive delivery because lipophilic compounds entrapped in Chi/PLGA particles 
when ingested with or without food would still exhibit a lower gastric drug release compared to 
PLGA; and, hence most of the compounds will be released mainly in the small intestine, where 
they are absorbed. The pH stability of Chi/PLGA particles indicated that these particles were 
stable with no detectable degradation caused by pH alone under all gastric conditions (Figure 
2.4).  
2.5 Conclusions 
Chi/PLGA particles synthesized by emulsion evaporation method with chitosan 
concentrations above 0.3 w/v % yielded stable, positively charged, spherical particles with an 
average size of 283 nm and potential of +58 mV. In comparison, PLGA particles measured 84 
nm in size with a negative potential of −55 mV. A change in αT initial loading had no effect on 
the particle properties or the vitamin entrapment efficiency. Morphology and particle properties 
indicated that Chi/PLGA particles were stable at acidic pHs below 5 and above 8 with an average 
size of 310 nm and 300 nm with a potential of + 40 mV and − 60 mV, respectively, and insoluble 
around the pKa of chitosan. Titration results indicated that the stability of PLGA particles was 
similar to lecithin/ αT emulsions, which approached the point of zero charge around pH 2.0 
where the particles precipitated. The gastric release of different intial loadings of αT showed that 
8% initial loading Chi/PLGA particles had a faster release of αT, when compared to 16 and 24 
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%; no difference in release was detected under intestinal conditions between the different alpha-
tocopherol initial loadings. Chi/PLGA particles had a slower αT initial release with 11 % 
compared to 24 % αT released by PLGA particles under basal and fed gastric conditions. 
Chi/PLGA particles also had a slower intestinal release rate, with a cumulative 58 % of αT 
released after 5 days compared to PLGA particles which released 82 % of αT in 5 days. 
Simulated gastrointestinal αT release revealed that Chi/PLGA particles released an average of 71 
% of entrapped αT, of which 40 % was released in the intestine, and PLGA particles 
approximately 90 % of entrapped αT in 5 days, of which 20 % was released in the intestine. It is 
concluded that Chi/PLGA particles were a better delivery system for αT, by ensuring that most 
of the αT was released in the intestine where absorption occurs; thus increasing the uptake and 
bioavailability of the lipophilic vitamin. 
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Chapter 3 Conclusions and Future Work 
3.1 Conclusions 
Mucoadhesive particles were desired for increased gastrointestinal residence time of 
lipophilic vitamins. Chitosan/PLGA particles were synthesized by emulsion evaporation method 
to yield stable, spherical and positively charged Chi/PLGA particles of 310 nm and + 50 Mv 
under acidic pHs; and stable, negatively charged particles of 300 nm and − 60 mV under high 
alkaline pHs. These particles exhibited a point of zero charge around neutral pHs varying 
between pH 5 to pH 8, where aggregation following by subsequent precipitation was visually 
observed. The point of zero charge of PLGA particles was detected around low acidic pHs of 2 
and lower, above which the particles were negatively charged. Different initial loading 
percentages of αT in Chi/PLGA particles were evaluated to determine the optimum entrapment 
in Chi/PLGA particles, and no significant difference in particle properties or percentage αT 
entrapped were observed. Hence, the median concentration was used for the follow-up studies to 
determine the in vitro release rate of αT in a simulated gastrointestinal environment.  
The simulated gastrointestinal release studies showed that the type of particle delivery 
system used has an effect on the amount released. A minimal gastric release of 20 % αT after 2 
hours under gastric conditions, and maximum αT release of 58 % was observed after 5 days 
under intestinal conditions using Chi/PLGA particles. In comparison, PLGA particles showed a 
59 % and 54 % under gastric and intestinal conditions, respectively, therefore Chi/PLGA 
particles are found more suitable for prolonged αT residence time in the GI tract.  
3.2 Future Work 
Chi/PLGA particles were unstable under neutral conditions, pH 5.5 to pH 8. 
Theoretically, positive charge is required for electrostatic attachment of the Chi/PLGA particles 
to the mucus tissue. Animal studies are recommended to ensure particle attachment under 
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intestinal conditions. Other studies include ex-vivo animal studies to determine the extent and 
length of Chi/PLGA attachment, to ensure increased particle retention and attachment to the 
mucus tissue, as opposed to whole nanoparticles translocation. Plasma αT concentration over 
time should be evaluated to study the effect of the Chi/PLGA particles on bioavailability of αT, 
via animal studies. It is also necessary to sample plasma concentration of αT before and after 
systemic circulation in order to differentiate between alpha-tocopherol direct intestinal uptake 
and alpha-tocopherol processed by the liver, via alpha-tocopherol transport protein. This would 
help in discriminating between the effect of the delivery system on the vitamin uptake and the 
percentage of absorbed vitamin that is actually available for tissue use, i.e. bioavailability. 
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Appendix A Particle Property Measurements Obtained by Dynamic Light 
Scattering 
Table A-1 The effect of chitosan concentration on particle properties with increasing chitosan 
concentration from 0.003 – 0.625 mg/mL on Chi/PLGA particles synthesized by emulsion 
evaporation. The particle properties were characterized using dynamic light scattering (Malvern 
Zetasizer Nanoseries)  
Chitosan 
Concn 
(mg/mL) 
EXPT 1 EXPT 2 EXPT 3 
Size 
(nm)  
Zeta 
(mV) 
PDI 
(a.u.) 
Size 
(nm)  
Zeta 
(mV) 
PDI 
(a.u.) 
Size 
(nm)  
Zeta 
(mV) 
PDI 
(a.u.) 
0.003 78.9 -54.20 0.156 78.6 -43.50 0.144 85.9 -50.00 0.231 
0.057 145.2 -32.90 0.344 83.5 -41.00 0.230 123.3 -53.20 0.263 
0.114 226.2 -36.80 0.366 138.8 -41.50 0.495 136.4 -40.70 0.300 
0.200 218.8 -38.50 0.286 225.5 -29.50 0.704 137.4 -42.70 0.319 
0.250 700.8 -14.50 0.724 9031 -16.00 0.501 373.8 -34.50 0.366 
0.275 5613.0 14.70 0.683 7431 15.90 0.811 1323 -21.70 0.773 
0.300 5236.0 31.30 0.742 368.9 41.80 0.289 18630 16.10 0.854 
0.325 3583.0 44.00 0.203 351.6 49.30 0.279 661.8 40.10 0.559 
0.350 1286.0 51.70 0.280 240.9 50.50 0.166 344.9 51.30 0.210 
0.375 900.0 55.50 0.231 254.5 50.00 0.207 309.5 52.90 0.194 
0.400 988.1 56.00 0.357 298.1 51.70 0.279 309.6 55.10 0.202 
0.425 761.4 53.80 0.566 291.1 52.30 0.268 266 55.00 0.203 
0.450 495.6 56.80 0.438 275.7 55.40 0.227 289 58.30 0.248 
0.475 500.0 56.70 0.440 273.0 54.60 0.214 270 57.20 0.209 
0.500 314.4 58.80 0.259 278.5 57.40 0.222 262.2 58.00 0.238 
0.525 380.3 55.80 0.360 313.7 56.00 0.258 260 56.00 0.240 
0.550 358.7 57.20 0.258 392.0 56.70 0.388 236.4 54.90 0.233 
0.575 375.9 57.10 0.277 271.7 56.00 0.210 259 61.10 0.253 
0.600 362.7 54.20 0.269 274.7 55.00 0.204 266.2 59.50 0.257 
0.625 295.8 62.20 0.255 267.3 60.00 0.208 298 59.60 0.205 
Table A-2 The effect of alpha-tocopherol initial loading on particle size, zeta-potential, and 
polydispersity on Chi/PLGA particles, without chitosan (PLGA particles), with chitosan before 
washing, and final particle properties after washing the particles. 
Without Chitosan With Chitosan before purification With Chitosan after purification 
Sys ini_L Size  Zeta PDI Sys ini_L Size  Zeta PDI Sys ini_L Size  Zeta PDI 
 
% nm Mv a.u. 
 
% nm Mv a.u. 
 
% nm Mv a.u. 
P 8 80.2 -34.7 0.207 CP 8 320.4 63.5 0.303 CP 8 490.5 53.0 0.210 
P 8 79.8 -35.6 0.190 CP 8 320.4 62.0 0.307 CP 8 485.9 51.9 0.202 
P 8 80.1 -36.1 0.220 CP 8 321.2 60.9 0.285 CP 8 483.3 52.8 0.181 
P 8 87.1 -38.2 0.214 CP 8 323.8 62.6 0.282 CP 8 507.8 52.9 0.220 
P 8 87.6 -55.3 0.179 CP 8 344.2 61.1 0.279 CP 8 504.0 53.3 0.232 
table continued 
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P 8 85.3 -64.0 0.198 CP 8 337.2 62.3 0.318 CP 8 518.0 53.9 0.196 
P 8 86.2 -47.3 0.166 CP 8 335.1 57.1 0.296 CP 8 546.2 52.3 0.234 
P 8 84.3 -49.5 0.166 CP 8 337.2 63.1 0.306 CP 8 541.2 53.7 0.215 
P 8 85.0 -52.3 0.194 CP 8 333.2 56.8 0.292 CP 8 535.7 52.7 0.173 
P 16 84.7 -36.4 0.240 CP 16 271.1 67.8 0.263 CP 16 268.8 38.0 0.101 
P 16 84.6 -44.7 0.230 CP 16 271.6 58.3 0.287 CP 16 267.2 37.9 0.172 
P 16 84.3 -38.9 0.223 CP 16 265.6 62.0 0.336 CP 16 266.9 36.7 0.161 
P 16 91.0 -53.9 0.189 CP 16 281.2 42.7 0.253 CP 16 266.2 45.4 0.147 
P 16 89.2 -53.7 0.191 CP 16 279.7 44.0 0.278 CP 16 266.6 42.0 0.146 
P 16 88.6 -65.4 0.213 CP 16 278.0 38.8 0.264 CP 16 260.2 46.4 0.147 
P 16 87.2 -56.4 0.148 CP 16 272.3 47.6 0.251 CP 16 284.9 42.4 0.119 
P 16 86.1 -53.0 0.158 CP 16 269.8 47.5 0.249 CP 16 275.9 39.4 0.135 
P 16 85.5 -51.5 0.186 CP 16 263.8 49.2 0.245 CP 16 275.3 40.8 0.118 
P 24 80.0 -27.5 0.174 CP 24 374.8 58.6 0.308 CP 24 402.4 47.0 0.180 
P 24 79.7 -26.7 0.183 CP 24 368.9 59.2 0.326 CP 24 393.4 48.7 0.173 
P 24 79.4 -32.8 0.189 CP 24 369.4 61.3 0.287 CP 24 397.3 48.1 0.224 
P 24 89.8 -30.2 0.171 CP 24 382.7 53.1 0.333 CP 24 503.1 48.0 0.230 
P 24 89.0 -27.8 0.159 CP 24 389.8 52.8 0.313 CP 24 503.8 53.8 0.238 
P 24 87.9 -29.7 0.170 CP 24 373.2 54.0 0.317 CP 24 502.6 46.9 0.208 
P 24 79.9 -29.5 0.165 CP 24 401.4 32.2 0.418 CP 24 492.2 46.3 0.303 
P 24 79.8 -29.1 0.167 CP 24 390.2 32.1 0.434 CP 24 487.5 45.5 0.285 
P 24 79.6 -33.6 0.182 CP 24 397.3 31.3 0.413 CP 24 478.2 45.5 0.273 
 
Table A-3 Chi/PLGA particle stability as a function of pH for 16% alpha-tocopherol initial 
loading over 24 hours 
 
Sys ini_L  pH   t Size zeta PDI pH   Size zeta PDI  pH   Size zeta PDI 
 
% 
 
hr nm mV a.u.  nm mV a.u. 
 
nm mV a.u. 
CP 16 1.5 0 347.2 30.00 0.419 4 437.8 50.9 0.226 5.5 269.4 32.7 0.280 
CP 16 1.5 0 313.1 28.60 0.349 4 441.6 51.4 0.23 5.5 259.1 30.5 0.255 
CP 16 1.5 0 306.9 29.00 0.382 4 409.2 52.5 0.183 5.5 249.4 32.1 0.234 
CP 16 1.5 3 385.2 30.50 0.467 4 461 49.9 0.233 5.5 268.5 33.0 0.245 
CP 16 1.5 3 330.9 30.70 0.415 4 466.7 50.5 0.25 5.5 252.7 32.1 0.271 
CP 16 1.5 3 328.1 28.70 0.357 4 429.2 50 0.218 5.5 246.3 32.7 0.221 
CP 16 1.5 6 383.9 30.20 0.465 4 468.3 51.2 0.214 5.5 264.0 33.4 0.253 
CP 16 1.5 6 367.3 28.50 0.42 4 464.4 52.4 0.241 5.5 281.8 32.0 0.323 
CP 16 1.5 6 351.3 28.70 0.477 4 438.1 51.9 0.195 5.5 277.3 32.3 0.285 
CP 16 1.5 24 476.2 30.60 0.618 4 432.6 48.9 0.233 5.5 2286 31.0 0.566 
CP 16 1.5 24 412.1 29.80 0.491 4 473.5 50.4 0.263 5.5 1182 30.9 0.308 
CP 16 1.5 24 373.8 30.80 0.443 4 435.6 52.6 0.198 5.5 1587 32.9 0.790 
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Table A-4 PLGA particle stability as a function of pH for 16% alpha-tocopherol initial loading 
over 24 hours 
Sys ini_L pH t Size zeta PDI pH Size  Zeta  PDI pH Size zeta PDI 
 
% 
 
hr nm mV a.u. 
 
nm mV a.u. 
 
nm mV a.u. 
P 16 6.5 0 85.58 -26.3 0.228 4 148.6 -51.9 0.398 5.5 107.9 -37.8 0.250 
P 16 6.5 0 143.9 -27.5 0.23 4 91.3 -51.1 0.225 5.5 147.8 -37.8 0.284 
P 16 6.5 0 157.3 -26.4 0.349 4 92.0 -54.8 0.253 5.5 132.6 -47.1 0.228 
P 16 6.5 3 86.54 -29.2 0.221 4 140.1 -42.8 0.367 5.5 114.2 -45.9 0.345 
P 16 6.5 3 141.9 -27.5 0.226 4 104.8 -21.5 0.258 5.5 161 -40.9 0.297 
P 16 6.5 3 133.5 -27.9 0.221 4 96.5 -55.1 0.262 5.5 129.4 -61.4 0.233 
P 16 6.5 6 86.21 -28.1 0.224 4 140.7 -48.3 0.381 5.5 138.5 -45.0 0.407 
P 16 6.5 6 141.2 -30.3 0.225 4 103.4 -35.1 0.231 5.5 137.5 -58.1 0.223 
P 16 6.5 6 139.3 -29.0 0.239 4 99.4 -49.2 0.318 5.5 132.4 -58.7 0.227 
P 16 6.5 24 87.53 -28.1 0.217 4 152.3 -47.3 0.393 5.5 104.5 -43.4 0.262 
P 16 6.5 24 136.6 -31.5 0.22 4 137.8 -21.4 0.330 5.5 140.1 -56.5 0.236 
P 16 6.5 24 137.9 -28.0 0.205 4 149.2 -46.6 0.415 5.5 129.7 -42.6 0.260 
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Appendix B Standard Curve for Alpha-tocopherol Detection by High 
Performance Liquid Chromatography  
Table B-5 Alpha-tocopherol standard curve raw data for reverse-phase HPLC detection for a 
concentration range of 20 – 1000 ng 
Concn (ng/ μL) Amt (ng) Inj Vol (μL) A-T 1 A-T 2 A-T 3 A-T 1 avg 
20 20 1 37.1 47.4 35.3 39.9 
20 100 5 194.4 202.9 202.0 199.8 
20 400 20 780.4 801.5 785.7 789.2 
20 600 30 1138.8 1153.7 1182.3 1158.3 
20 1000 50 2066.5 2088.5 2083.1 2079.4 
20 20 1 40.0 42.8 39.9 40.9 
20 100 5 220.7 216.2 214.4 217.1 
20 400 20 842.8 860.3 860.4 854.5 
20 600 30 1344.3 1335.7 1335.9 1338.6 
20 1000 50 2259.2 2264.4 2259.8 2261.1 
20 20 1 41.2 39.9 40.7 40.6 
20 100 5 211.4 207.3 208.6 209.1 
20 400 20 826.9 815.6 794.4 812.3 
20 600 30 1330.3 1333.6 1331.5 1331.8 
20 1000 50 2213.6 2234.5 2172.8 2207.0 
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Figure B. 1 Alpha-tocopherol standard curve for HPLC detection with a regression co-efficient 
of 0.9996 
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Appendix C Alpha-tocopherol Gastric Release Data  
Table C-6 Gastric release of alpha-tocopherol from 8% initial loading Chi/PLGA particles at 
pH 1.5, basal state conditions over 2 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 160 161 74.28 74.74 94.15 21% 21% 21% 
0.5 25 157.4 155.1 73.07 72.01 94.15 22% 24% 23% 
1.5 25 131.6 129.5 61.10 60.12 94.15 35% 36% 36% 
3 25 107.8 105.3 50.05 48.89 94.15 47% 48% 47% 
6 25 17.6 17 8.17 7.89 94.15 91% 92% 91% 
12 25 15.8 13.3 7.34 6.17 94.15 92% 93% 93% 
24 25 10.5 11.3 4.87 5.25 94.15 95% 94% 95% 
48 25 4.8 2.3 2.23 1.07 94.15 98% 99% 98% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 97.3 91.5 45.17 42.48 61.64 27% 31% 29% 
0.5 25 90.2 91.4 41.88 42.43 61.64 32% 31% 32% 
1.5 25 74.5 72.3 34.59 33.57 61.64 44% 46% 45% 
3 25 61 58.2 28.32 27.02 61.64 54% 56% 55% 
6 25 20.7 14.9 9.61 6.92 61.64 84% 89% 87% 
12 25 15.1 15.4 7.01 7.15 61.64 89% 88% 89% 
24 25 10.7 9.7 4.97 4.50 61.64 92% 93% 92% 
48 25 7.2 8.7 3.34 4.04 61.64 95% 93% 94% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 119.1 117.5 55.29 54.55 70.51 22% 23% 22% 
0.5 25 117.5 116.3 54.55 53.99 70.51 23% 23% 23% 
1.5 25 80.3 78.3 37.28 36.35 70.51 47% 48% 48% 
3 25 70 69.6 32.50 32.31 70.51 54% 54% 54% 
6 25 38.1 39.5 17.69 18.34 70.51 75% 74% 74% 
12 25 28.4 27.9 13.18 12.95 70.51 81% 82% 81% 
24 25 22.9 21.7 10.63 10.07 70.51 85% 86% 85% 
48 25 8.2 9.4 3.81 4.36 70.51 95% 94% 94% 
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Table C-7 Gastric release of alpha-tocopherol from 16% initial loading PLGA particles at pH 
1.5, basal state conditions over 2 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 470.8 465.1 218.5701 215.9239 266.06 18% 19% 18% 
0.5 25 369.2 355.9 171.402 165.2275 266.06 36% 38% 37% 
1.5 25 289.4 294.7 134.3547 136.8152 266.06 50% 49% 49% 
3 25 291.1 286.2 135.1439 132.8691 266.06 49% 50% 50% 
6 25 281.8 276.8 130.8264 128.5051 266.06 51% 52% 51% 
12 25 215.8 211.8 100.1857 98.32869 266.06 62% 63% 63% 
24 25 130.1 134.9 60.39926 62.62767 266.06 77% 76% 77% 
48 25 109.3 108.2 50.7428 50.23213 266.06 81% 81% 81% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 206.6 206 95.91 95.64 157.31 39% 39% 39% 
0.5 25 186.2 182.2 86.44 84.59 157.31 45% 46% 46% 
1.5 25 121 120.5 56.17 55.94 157.31 64% 64% 64% 
3 25 92.2 90.1 42.80 41.83 157.31 73% 73% 73% 
6 25 72.6 72.7 33.70 33.75 157.31 79% 79% 79% 
12 25 70.6 67.5 32.78 31.34 157.31 79% 80% 80% 
24 25 65.2 64.1 30.27 29.76 157.31 81% 81% 81% 
48 25 32.8 31.4 15.23 14.58 157.31 90% 91% 91% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 196.9 191.9 91.41 89.09 106.98 15% 17% 16% 
0.5 25 151.8 148.9 70.47 69.13 106.98 34% 35% 35% 
1.5 25 89.1 88.7 41.36 41.18 106.98 61% 62% 61% 
3 25 86.5 85 40.16 39.46 106.98 62% 63% 63% 
6 25 74.1 73.2 34.40 33.98 106.98 68% 68% 68% 
12 25 68.6 69.2 31.85 32.13 106.98 70% 70% 70% 
24 25 55.4 57.2 25.72 26.56 106.98 76% 75% 76% 
48 25 27.4 26.1 12.72 12.12 106.98 88% 89% 88% 
 
Table C-8 Gastric release of alpha-tocopherol from 16% initial loading PLGA particles at pH 4, 
fed state conditions over 2 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 597 619 277.1588 287.3723 356.64 22% 19% 21% 
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0.5 25 371.9 376.3 172.6555 174.6982 356.64 52% 51% 51% 
1.5 25 354 373.1 164.3454 173.2126 356.64 54% 51% 53% 
3 25 264.4 268.1 122.7484 124.4661 356.64 66% 65% 65% 
6 25 251 252.9 116.5274 117.4095 356.64 67% 67% 67% 
12 25 123 121.1 57.10306 56.22098 356.64 84% 84% 84% 
24 25 46.9 48.8 21.77344 22.65552 356.64 94% 94% 94% 
48 25 19.8 21.6 9.192201 10.02786 356.64 97% 97% 97% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 561.8 563.9 260.82 261.79 308.0719 15% 15% 15% 
0.5 25 557.1 558.1 258.64 259.10 308.0719 16% 16% 16% 
1.5 25 487 479 226.09 222.38 308.0719 27% 28% 27% 
3 25 332.4 333.1 154.32 154.64 308.0719 50% 50% 50% 
6 25 298.7 300.4 138.67 139.46 308.0719 55% 55% 55% 
12 25 200.1 223.1 92.90 103.57 308.0719 70% 66% 68% 
24 25 89.3 89.8 41.46 41.69 308.0719 87% 86% 87% 
48 25 26.9 26.8 12.49 12.44 308.0719 96% 96% 96% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 672.9 673.3 312.40 312.58 438.5095 29% 29% 29% 
0.5 25 591.5 600.8 274.61 278.92 438.5095 37% 36% 37% 
1.5 25 567.6 578.2 263.51 268.43 438.5095 40% 39% 39% 
3 25 549.7 546.9 255.20 253.90 438.5095 42% 42% 42% 
6 25 401.3 402.1 186.30 186.68 438.5095 58% 57% 57% 
table contd. 
12 25 229.5 223.1 106.55 103.57 438.5095 76% 76% 76% 
24 25 102.2 107.9 47.45 50.09 438.5095 89% 89% 89% 
48 25 24.6 24.8 11.42 11.51 438.5095 97% 97% 97% 
Table C-9 Gastric release of alpha-tocopherol from 16% initial loading Chi/PLGA particles at 
pH 1.5, basal state conditions over 2 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 495.7 501.3 230.13 232.7298 237.39 3% 2% 3% 
0.5 25 482 471 223.7697 218.663 237.39 6% 8% 7% 
1.5 25 391.9 390.1 181.9406 181.1049 237.39 23% 24% 24% 
3 25 387 384.4 179.6657 178.4587 237.39 24% 25% 25% 
6 25 307.9 313.2 142.9434 145.4039 237.39 40% 39% 39% 
12 25 286.8 286.2 133.1476 132.8691 237.39 44% 44% 44% 
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24 25 231.4 228.7 107.428 106.1746 237.39 55% 55% 55% 
48 25 113.9 117.6 52.87837 54.5961 237.39 78% 77% 77% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 338.7 338.7 157.2423 157.2423 185.90 15% 15% 15% 
0.5 25 316.6 321.4 146.9824 149.2108 185.90 21% 20% 20% 
1.5 25 264.7 261 122.8877 121.1699 185.90 34% 35% 34% 
3 25 229.6 217.4 106.5924 100.9285 185.90 43% 46% 44% 
6 25 157 148.8 72.88765 69.08078 185.90 61% 63% 62% 
12 25 129.5 129.3 60.12071 60.02786 185.90 68% 68% 68% 
24 25 100.9 98.2 46.84308 45.5896 185.90 75% 75% 75% 
48 25 68 76 31.56917 35.28319 185.90 83% 81% 82% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 277.3 277.5 128.7372 128.8301 153.98 16% 16% 16% 
0.5 25 259.8 253.6 120.6128 117.7344 153.98 22% 24% 23% 
1.5 25 240.7 239.2 111.7456 111.0492 153.98 27% 28% 28% 
3 25 228.8 224.7 106.221 104.3175 153.98 31% 32% 32% 
6 25 182.6 172.7 84.77252 80.17642 153.98 45% 48% 46% 
12 25 162.3 164.6 75.34819 76.41597 153.98 51% 50% 51% 
24 25 35.6 35.5 16.52739 16.48097 153.98 89% 89% 89% 
48 25 27.8 28.8 12.90622 13.37047 153.98 92% 91% 91% 
Table C-10 Gastric release of alpha-tocopherol from 16% initial loading Chi/PLGA particles at 
pH 4, fed state conditions over 2 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 850 853 394.6147 396.0074 475.46 17% 17% 17% 
0.5 25 740.5 734.2 343.779 340.8542 475.46 28% 28% 28% 
1.5 25 690.6 689.9 320.6128 320.2878 475.46 33% 33% 33% 
3 25 600.2 610.2 278.6444 283.2869 475.46 41% 40% 41% 
6 25 570.2 574.3 264.7168 266.6202 475.46 44% 44% 44% 
12 25 489.1 487.2 227.0659 226.1838 475.46 52% 52% 52% 
24 25 335.6 329 155.8032 152.7391 475.46 67% 68% 68% 
48 25 129 131 59.88858 60.81708 475.46 87% 87% 87% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 780.8 762.5 362.49 353.99 384.94 6% 8% 7% 
0.5 25 750.2 758.5 348.28 352.14 384.94 10% 9% 9% 
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1.5 25 727.9 711.8 337.93 330.45 384.94 12% 14% 13% 
3 25 681.1 667.5 316.20 309.89 384.94 18% 19% 19% 
6 25 569.2 574.4 264.25 266.67 384.94 31% 31% 31% 
12 25 440.1 443.2 204.32 205.76 384.94 47% 47% 47% 
24 25 316.3 310.1 146.84 143.96 384.94 62% 63% 62% 
48 25 128.5 132.9 59.66 61.70 384.94 85% 84% 84% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 758.8 758.6 352.27 352.18 403.77 13% 13% 13% 
0.5 25 756.6 752.8 351.25 349.49 403.77 13% 13% 13% 
1.5 25 745.6 752.1 346.15 349.16 403.77 14% 14% 14% 
3 25 702.6 689.7 326.18 320.19 403.77 19% 21% 20% 
6 25 635.8 628.8 295.17 291.92 403.77 27% 28% 27% 
12 25 545.5 547.2 253.25 254.04 403.77 37% 37% 37% 
24 25 363.3 364.9 168.66 169.41 403.77 58% 58% 58% 
48 25 162.2 163.6 75.30 75.95 403.77 81% 81% 81% 
Table C-11 Gastric release of alpha-tocopherol from 24% initial loading Chi/PLGA particles at 
pH 1.5, basal state conditions over 2 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 520.54 525.5 241.66 243.96 283.30 15% 14% 14% 
0.5 25 502.2 508.5 233.15 236.07 283.30 18% 17% 17% 
1.5 25 495.3 501.3 229.94 232.73 283.30 19% 18% 18% 
3 25 475.3 478.9 220.66 222.33 283.30 22% 22% 22% 
6 25 398.8 389.1 185.14 180.64 283.30 35% 36% 35% 
12 25 300.1 298.3 139.32 138.49 283.30 51% 51% 51% 
24 25 222.6 220.1 103.34 102.18 283.30 64% 64% 64% 
48 25 108.1 104.2 50.19 48.38 283.30 82% 83% 83% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 807.5 828.8 374.88 384.77 426.74 12% 10% 11% 
0.5 25 800.4 794.8 371.59 368.99 426.74 13% 14% 13% 
1.5 25 742.2 777.2 344.57 360.82 426.74 19% 15% 17% 
3 25 599.7 603.3 278.41 280.08 426.74 35% 34% 35% 
6 25 407.7 403 189.28 187.09 426.74 56% 56% 56% 
12 25 381.1 387 176.93 179.67 426.74 59% 58% 58% 
24 25 280.5 282 130.22 130.92 426.74 69% 69% 69% 
48 25 232.8 237.7 108.08 110.35 426.74 75% 74% 74% 
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Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 576.7 577.8 267.73 268.25 303.81 12% 12% 12% 
0.5 25 541.6 535.2 251.44 248.47 303.81 17% 18% 18% 
1.5 25 533.7 538 247.77 249.77 303.81 18% 18% 18% 
3 25 517 520.8 240.02 241.78 303.81 21% 20% 21% 
6 25 402.2 399.7 186.72 185.56 303.81 39% 39% 39% 
12 25 378 365 175.49 169.45 303.81 42% 44% 43% 
24 25 220.4 229.4 102.32 106.50 303.81 66% 65% 66% 
48 25 203.6 203.8 94.52 94.61 303.81 69% 69% 69% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
Appendix D Alpha-tocopherol Intestinal Release Data 
Table D- 1 Intestinal release of alpha-tocopherol from 8% initial loading Chi/PLGA particles at 
pH 6.5, basal state intestinal conditions over 5 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 255 249.3 117.67 115.04 115.88 -2% 1% 0% 
4 25 234.4 221.1 108.17 102.03 115.88 7% 12% 9% 
8 25 196.5 194.5 90.68 89.76 115.88 22% 23% 22% 
24 25 154.6 151.1 71.34 69.73 115.88 38% 40% 39% 
48 25 143.8 146.2 66.36 67.47 115.88 43% 42% 42% 
72 25 114.5 109.5 52.84 50.53 115.88 54% 56% 55% 
96 25 92.6 89.1 42.73 41.12 115.88 63% 65% 64% 
120 25 64.6 69.6 29.81 32.12 115.88 74% 72% 73% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 206.5 204.2 95.87 94.80 101.70 6% 7% 6% 
4 25 187 178.2 86.82 82.73 101.70 15% 19% 17% 
8 25 154.1 155.3 71.54 72.10 101.70 30% 29% 29% 
24 25 137.7 135.4 63.93 62.86 101.70 37% 38% 38% 
48 25 125.2 126 58.12 58.50 101.70 43% 42% 43% 
72 25 121 122.7 56.17 56.96 101.70 45% 44% 44% 
96 25 67.9 69.6 31.52 32.31 101.70 69% 68% 69% 
120 25 29.9 31 13.88 14.39 101.70 86% 86% 86% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 186.6 186.2 86.63 86.44 88.14 2% 2% 2% 
4 25 179.6 173.2 83.38 80.41 88.14 5% 9% 7% 
8 25 152.8 146.9 70.94 68.20 88.14 20% 23% 21% 
24 25 120.1 123 55.76 57.10 88.14 37% 35% 36% 
48 25 115.3 113.5 53.53 52.69 88.14 39% 40% 40% 
72 25 100.1 103.2 46.47 47.91 88.14 47% 46% 46% 
96 25 90.5 91.5 42.01 42.48 88.14 52% 52% 52% 
120 25 30.1 31.2 13.97 14.48 88.14 84% 84% 84% 
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Table D- 2 Intestinal release of alpha-tocopherol from 16% initial loading PLGA particles at pH 
6.5, basal state intestinal conditions over 5 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 310 316.4 143.92 146.89 145.63 1.18% -0.86% 0.16% 
4 25 289.8 278.5 134.54 129.29 145.63 7.62% 11.22% 9.42% 
8 25 255.6 259.5 118.66 120.47 145.63 18.52% 17.28% 17.90% 
24 25 221.9 228.8 103.02 106.22 145.63 29.26% 27.06% 28.16% 
48 25 214.4 213.9 99.54 99.30 145.63 31.65% 31.81% 31.73% 
72 25 202.1 200.1 93.83 92.90 145.63 35.57% 36.21% 35.89% 
96 25 195.4 190.6 90.71 88.49 145.63 37.71% 39.24% 38.48% 
120 25 113.7 117.5 52.79 54.55 145.63 63.75% 62.54% 63.15% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 177.1 177.1 82.22 82.22 122.99 33.15% 33.15% 33.15% 
4 25 173.7 175.2 80.64 81.34 122.99 34.43% 33.87% 34.15% 
8 25 172.8 170.9 80.22 79.34 122.99 34.77% 35.49% 35.13% 
24 25 171.3 170.5 79.53 79.16 122.99 35.34% 35.64% 35.49% 
48 25 164 160 76.14 74.28 122.99 38.09% 39.60% 38.85% 
72 25 162.4 158.9 75.39 73.77 122.99 38.70% 40.02% 39.36% 
96 25 151.3 142.4 70.24 66.11 122.99 42.89% 46.25% 44.57% 
120 25 138.6 137.8 64.35 63.97 122.99 47.68% 47.98% 47.83% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 186.6 186.2 86.63 86.44 115.20 24.80% 24.97% 24.88% 
4 25 179.6 173.2 83.38 80.41 115.20 27.62% 30.20% 28.91% 
8 25 152.8 146.9 70.94 68.20 115.20 38.42% 40.80% 39.61% 
24 25 146.4 148.6 67.97 68.99 115.20 41.00% 40.12% 40.56% 
48 25 143 147.5 66.39 68.48 115.20 42.37% 40.56% 41.47% 
72 25 142 141.9 65.92 65.88 115.20 42.78% 42.82% 42.80% 
96 25 138.4 135 64.25 62.67 115.20 44.23% 45.60% 44.91% 
120 25 118.7 119.6 55.11 55.52 115.20 52.17% 51.80% 51.98% 
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Table D- 3 Intestinal release of alpha-tocopherol from 16% initial loading PLGA particles at pH 
5.5, fed state intestinal conditions over 5 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 280 285 129.991 132.312 162.44 19.98% 18.55% 19.26% 
4 25 244.2 246.2 113.37 114.299 162.44 30.21% 29.64% 29.92% 
8 25 243.2 248.6 112.906 115.413 162.44 30.49% 28.95% 29.72% 
24 25 239.6 244.5 111.235 113.51 162.44 31.52% 30.12% 30.82% 
48 25 227.6 227.7 105.664 105.71 162.44 34.95% 34.92% 34.94% 
72 25 142.4 146.4 66.1096 67.9666 162.44 59.30% 58.16% 58.73% 
96 25 144.5 144.6 67.0845 67.1309 162.44 58.70% 58.67% 58.69% 
120 25 73.5 72.8 34.1226 33.7976 162.44 78.99% 79.19% 79.09% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 189 189.5 87.7437 87.9759 128.71 31.83% 31.65% 31.74% 
4 25 175.9 176.4 81.662 81.8942 128.71 36.55% 36.37% 36.46% 
8 25 169.1 171.8 78.5051 79.7586 128.71 39.01% 38.03% 38.52% 
24 25 152 154.4 70.5664 71.6806 128.71 45.17% 44.31% 44.74% 
48 25 146.9 143.6 68.1987 66.6667 128.71 47.01% 48.20% 47.61% 
72 25 134.5 136.9 62.442 63.5562 128.71 51.49% 50.62% 51.05% 
96 25 74.6 70.6 34.6332 32.7762 128.71 73.09% 74.54% 73.81% 
120 25 59.6 59.2 27.6695 27.4838 128.71 78.50% 78.65% 78.57% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 176.8 181 82.0799 84.0297 128.92 36.33% 34.82% 35.58% 
4 25 176.4 175.7 81.8942 81.5692 128.92 36.48% 36.73% 36.60% 
8 25 154.5 154.2 71.727 71.5877 128.92 44.36% 44.47% 44.42% 
24 25 150.9 145.5 70.0557 67.5487 128.92 45.66% 47.60% 46.63% 
48 25 118.5 114.6 55.0139 53.2033 128.92 57.33% 58.73% 58.03% 
72 25 89.3 86.4 41.4578 40.1114 128.92 67.84% 68.89% 68.36% 
96 25 91 88 42.247 40.8542 128.92 67.23% 68.31% 67.77% 
120 25 37.7 33.6 17.5023 15.5989 128.92 86.42% 87.90% 87.16% 
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Table D- 4 Intestinal release of alpha-tocopherol from 16% initial loading Chi/PLGA particles at 
pH 6.5, basal state intestinal conditions over 5 days 
Time 
(hrs) 
Inj Vol 
(uL) 
AUC1 (f.u.) 
Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 271.7 263.1 126.1374 122.1448 147.564 14.52% 17.23% 15.87% 
4 25 248.2 250.4 115.2275 116.2488 147.564 21.91% 21.22% 21.57% 
8 25 243.5 235.4 113.0455 109.2851 147.564 23.39% 25.94% 24.67% 
24 25 185.1 191.3 85.93315 88.81151 147.564 41.77% 39.81% 40.79% 
48 25 185.6 192.4 86.16527 89.32219 147.564 41.61% 39.47% 40.54% 
72 25 179.6 177.8 83.37976 82.5441 147.564 43.50% 44.06% 43.78% 
96 25 111.5 109.8 51.76416 50.97493 147.564 64.92% 65.46% 65.19% 
120 25 98 80 45.49675 37.1402 147.564 69.17% 74.83% 72.00% 
Time 
(hrs) 
Inj Vol 
(uL) 
AUC2 (f.u.) 
Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 330 329 153.2033 152.7391 159.807 4.13% 4.42% 4.28% 
4 25 322.1 324.3 149.5357 150.5571 159.807 6.43% 5.79% 6.11% 
8 25 256.8 261.4 119.2201 121.3556 159.807 25.40% 24.06% 24.73% 
24 25 243.9 253 113.2312 117.4559 159.807 29.15% 26.50% 27.82% 
48 25 244.6 251.8 113.5562 116.8988 159.807 28.94% 26.85% 27.90% 
72 25 231.8 232.7 107.6137 108.0316 159.807 32.66% 32.40% 32.53% 
96 25 210.4 199.4 97.67874 92.57196 159.807 38.88% 42.07% 40.47% 
120 25 189.8 189.9 88.11513 88.16156 159.807 44.86% 44.83% 44.85% 
Time 
(hrs) 
Inj Vol 
(uL) 
AUC3 (f.u.)       
Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 283.9 285.2 131.8013 132.4048 134.732 2.18% 1.73% 1.95% 
4 25 248.3 250.3 115.2739 116.2024 134.732 14.44% 13.75% 14.10% 
8 25 229.9 231.2 106.7317 107.3352 134.732 20.78% 20.33% 20.56% 
24 25 227.1 216.1 105.4318 100.325 134.732 21.75% 25.54% 23.64% 
48 25 175.7 167 81.56917 77.53018 134.732 39.46% 42.46% 40.96% 
72 25 144.4 141.4 67.03807 65.64531 134.732 50.24% 51.28% 50.76% 
96 25 129.2 124.5 59.98143 57.79944 134.732 55.48% 57.10% 56.29% 
120 25 123.6 123.5 57.38162 57.33519 134.732 57.41% 57.45% 57.43% 
Table D- 5 Intestinal release of alpha-tocopherol from 16% initial loading Chi/PLGA particles at 
pH 5.5, fed state intestinal conditions over 5 days 
Time  
(hrs) 
Inj Vol  
(uL) 
AUC1 (f.u.) 
Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 320 325.2 148.5608 150.9749 153.98 3.52% 1.95% 2.74% 
4 25 305.7 303.5 141.922 140.9006 153.98 7.83% 8.49% 8.16% 
8 25 282.6 263.6 131.1978 122.377 153.98 14.80% 20.52% 17.66% 
24 25 254.8 252.8 118.2916 117.363 153.98 23.18% 23.78% 23.48% 
48 25 229.2 229.4 106.4067 106.4995 153.98 30.90% 30.84% 30.87% 
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72 25 214.6 204.4 99.6286 94.89322 153.98 35.30% 38.37% 36.84% 
96 25 164.2 159.2 76.23027 73.90901 153.98 50.49% 52.00% 51.25% 
120 25 121.1 121.4 56.22098 56.36026 153.98 63.49% 63.40% 63.44% 
Time  
(hrs) 
Inj Vol  
(uL) 
AUC2 (f.u.) 
Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 360.7 381.6 167.4559 177.1588 195.68 14.42% 9.47% 11.95% 
4 25 352 361.5 163.4169 167.8273 195.68 16.49% 14.23% 15.36% 
8 25 322.7 321.9 149.8143 149.4429 195.68 23.44% 23.63% 23.53% 
24 25 288.7 296.1 134.0297 137.4652 195.68 31.51% 29.75% 30.63% 
48 25 266.3 270.8 123.6305 125.7196 195.68 36.82% 35.75% 36.29% 
72 25 234.6 233.3 108.9136 108.3101 195.68 44.34% 44.65% 44.50% 
96 25 177.8 173.2 82.5441 80.40854 195.68 57.82% 58.91% 58.36% 
120 25 129.7 123.4 60.21356 57.28877 195.68 69.23% 70.72% 69.98% 
Time 
(hrs) 
Inj Vol 
(uL) 
AUC3 (f.u.) 
Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 233.3 240.2 108.3101 111.5135 125.11 13.43% 10.87% 12.15% 
4 25 224.7 234.1 104.3175 108.6815 125.11 16.62% 13.13% 14.87% 
8 25 207.1 210.7 96.1467 97.81801 125.11 23.15% 21.81% 22.48% 
24 25 200.4 202.4 93.03621 93.96472 125.11 25.64% 24.89% 25.26% 
48 25 199.2 194 92.47911 90.065 125.11 26.08% 28.01% 27.05% 
72 25 193.2 188.8 89.69359 87.65088 125.11 28.31% 29.94% 29.12% 
96 25 156.6 150 72.70195 69.63788 125.11 41.89% 44.34% 43.11% 
120 25 116.7 119.2 54.17827 55.3389 125.11 56.69% 55.77% 56.23% 
Table D- 6 Intestinal release of alpha-tocopherol from 24% initial loading Chi/PLGA particles at 
pH 6.5, basal state intestinal conditions over 5 days 
Time  Inj Vol  AUC1 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR1 
0 25 522.9 523.3 242.76 242.94 227.57 -7% -7% -7% 
4 25 456 440 211.70 204.27 227.57 7% 10% 9% 
8 25 395.3 390.9 183.52 181.48 227.57 19% 20% 20% 
24 25 319.5 321.3 148.33 149.16 227.57 35% 34% 35% 
48 25 302.3 300.9 140.34 139.69 227.57 38% 39% 38% 
72 25 242.8 240.6 112.72 111.70 227.57 50% 51% 51% 
96 25 197.5 207.2 91.69 96.19 227.57 60% 58% 59% 
120 25 95.8 94.1 44.48 43.69 227.57 80% 81% 81% 
Time  Inj Vol  AUC2 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR2 
0 25 997.6 989.5 463.14 459.38 445.09 -4% -3% -4% 
4 25 850.7 857.2 394.94 397.96 445.09 11% 11% 11% 
8 25 684.4 714.4 317.73 331.66 445.09 29% 25% 27% 
68 
 
24 25 418 426.2 194.06 197.86 445.09 56% 56% 56% 
48 25 370 372.3 171.77 172.84 445.09 61% 61% 61% 
72 25 310.4 305.6 144.10 141.88 445.09 68% 68% 68% 
96 25 258.3 260.1 119.92 120.75 445.09 73% 73% 73% 
120 25 98.7 99.1 45.82 46.01 445.09 90% 90% 90% 
Time Inj Vol AUC3 (f.u.) 
(hrs) (uL) Rep A1 Rep A2 αT1 (ng) αT2 (ng) αTini (ng) % R1-1 % R1-2 % TR3 
0 25 489.3 490.3 227.16 227.62 221.70 -2% -3% -3% 
4 25 439.1 435.7 203.85 202.27 221.70 8% 9% 8% 
8 25 300.4 299.1 139.46 138.86 221.70 37% 37% 37% 
24 25 179.6 173.2 83.38 80.41 221.70 62% 64% 63% 
48 25 167 169.1 77.53 78.51 221.70 65% 65% 65% 
72 25 142 141.9 65.92 65.88 221.70 70% 70% 70% 
96 25 120.9 122 56.13 56.64 221.70 75% 74% 75% 
120 25 96 93.9 44.57 43.59 221.70 80% 80% 80% 
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